


Burns' Pediatric Primary Care 8th Edition PDF

Visit the link below to download the full version of the ebook

[DOWNLOAD NOW](#)




Scan to Download
or Type the Link

ebook.ac/burns8e

8th
EDITION

BURNS'



Pediatric Primary Care

Dawn Lee Garzon
Mary Dirks
Martha Driessnack
Karen G. Duderstadt
Nan M. Gaylord



<http://evolve.elsevier.com>

Contents

- 1 Pediatric Primary Care, 1
- 2 Global and National Influences on Child Health Status, 6
- 3 Environmental Influences on Pediatric Health, 12
- 4 Justice, Equity, Inclusion, and Diversity, 27
- 5 Pediatric and Family Assessment, 31
- 6 Behavioral and Mental Health Promotion, 38
- 7 Sexuality and Gender Identity, 70
- 8 Developmental Principles and Theories, 83
- 9 Developmental Management of Newborns and Neonates, 91
- 10 Developmental Management of Infants, 103
- 11 Developmental Management of Early Childhood, 120
- 12 Developmental Management of Middle Childhood, 139
- 13 Developmental Management of Adolescents, 153
- 14 Nutrition, 171
- 15 Breastfeeding, 190
- 16 Sleep, 206
- 17 Elimination, 216
- 18 Physical Activity and Sports, 231
- 19 Immunizations, 265
- 20 Dental and Oral Health, 283
- 21 Pediatric Injury Prevention, 299
- 22 Child Maltreatment, 306
- 23 Prescribing Traditional and Complementary Therapies, 320
- 24 Pediatric Pain and Fever Management, 329
- 25 Pediatric Injuries and Toxic Exposures, 345
- 26 Pediatric Palliative Care, 365
- 27 Congenital and Inherited Disorders, 376
- 28 Neonatal Disorders, 395
- 29 Neurodivergence and Behavioral and Mental Health Disorders, 419
- 30 Eye and Vision Disorders, 456
- 31 Ear and Hearing Disorders, 485
- 32 Respiratory Disorders, 503
- 33 Cardiovascular Disorders, 536
- 34 Gastrointestinal Disorders, 566
- 35 Infectious Diseases, 610
- 36 Inflammatory Disorders, 659
- 37 Dermatologic Disorders, 709
- 38 Hematologic Disorders, 767
- 39 Endocrine and Metabolic Disorders, 799
- 40 Musculoskeletal Disorders, 841
- 41 Neurologic Disorders, 874
- 42 Genitourinary Disorders, 908
- 43 Gynecology and Reproductive Health, 934
- Appendix, 968
- Index, 971

Burns' Pediatric Primary Care

This page intentionally left blank

Burns' Pediatric Primary Care

EIGHTH EDITION

Editors

**Dawn Lee Garzon, PhD, RN, CPNP-PC,
PMHS, FAANP, FAAN**

Nurse Practitioner
Department of Child and Adolescent Psychiatry
Washington University School of Medicine
St. Louis, Missouri

**Mary Dirks, DNP, RN, ARNP, CPNP-PC,
FAANP, ELAN Fellow**

Co-Lead Editor
Clinical Professor
College of Nursing
The University of Iowa
Iowa City, Iowa

Martha Driessnack, PhD, RN, PNP

Emerita Faculty
School of Nursing
Oregon Health & Science University
Portland, Oregon

**Karen G. Duderstadt, PhD, RN, CPNP-PC,
FAAN**

Clinical Professor Emerita
Department of Family Health Care Nursing
School of Nursing
University of California San Francisco
San Francisco, California

**Nan M. Gaylord PhD, RN, CPNP-PC,
PMHS, FAANP, FAAN**

Professor
College of Nursing
University of Tennessee
Knoxville, Tennessee

Associate Editors

Jaime Panton, DNP, CPNP-AC/PC

Associate Professor
School of Nursing
Columbia University
New York, New York

**Daniel Crawford, DNP, ARNP, CPNP-PC,
CNE, FAANP**

Clinical Associate Professor
College of Nursing
The University of Iowa
Iowa City, Iowa



ELSEVIER
3251 Riverport Lane
St. Louis, Missouri 63043

BURNS' PEDIATRIC PRIMARY CARE, EIGHTH EDITION
Copyright © 2025 by Elsevier, Inc. All rights reserved.

ISBN: 978-0-323-88231-6

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: <http://elsevier.com/permissions>.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Previous editions copyright © 2020, 2017, 2013, 2009, 2004, 2000, and 1996.

Senior Content Strategist: Sandra Clark
Senior Content Development Specialist: Laura Selkirk
Publishing Services Manager: Catherine Jackson
Senior Project Manager/Specialist: Carrie Stetz
Book Design: Maggie Reid

Printed in India

Last digit is the print number: 9 8 7 6 5 4 3 2 1



This edition is dedicated to the timeless leadership, professional expertise, and dedication of our emeriti authors who nurtured this text through the years. With this edition, the ranks of emeriti grow from three to five. The role of emeriti is not guaranteed but is a special acknowledgement of their outstanding contribution to the text and our profession. These authors are mentors to countless people, role models to thousands, and tireless advocates for millions of children and their families. They helped to shape pediatric-focused advanced practice and set high standards for best pediatric care, and they are the best role models of pediatric primary care providers. We are honored to be their friends and colleagues, and we are better pediatric nurse practitioners because of our association with them. We hope this edition celebrates their renowned legacy while continuing to honor their purpose and passion.

With deepest thanks and sincere admiration to:

Margaret A. Brady, PhD, RN, CPNP-PC

Director
Pediatric Nurse Practitioner Program
Azusa Pacific University
Azusa, California

Nancy Barber Starr, MS, RN, CPNP

Pediatric Nurse Practitioner
Advanced Pediatric Associates
Centennial, Colorado

Catherine E. Burns, PhD, RN, CPNP-PC, FAAN

Professor Emeritus
Primary Health Care Nurse Practitioner Specialty
School of Nursing
Oregon Health & Science University
Portland, Oregon

Ardys M. Dunn, PhD, RN, PNP

Associate Professor, Emeritus
University of Portland School of Nursing
Portland, Oregon
Professor (Retired)
Samuel Merritt College School of Nursing
Oakland, California

Catherine G. Blosser, MPA, HA, RN, PNP

Pediatric Nurse Practitioner (Retired)
Multnomah County Health Department
Portland, Oregon

Contributors

Andrea Achenbach, DNP, ARNP, FNP-C

Clinical Assistant Professor
College of Nursing
The University of Iowa
Iowa City, Iowa

Britta G. Beblavi, RDN, CD, LD

Owner, Registered Dietitian
Grow Well Nutrition LLC
Greenwood Village, Colorado

Tami B. Bland, DNP, CPNP-PC

Clinical Associate Professor
College of Nursing
University of Tennessee
Knoxville, Tennessee

Jodi Bloxham, DNP, ARNP, CPNP-AC, CPNP-PC

Assistant Professor (Clinical) and Director
Pediatric Acute Care Nurse Practitioner Program
The University of Iowa College of Nursing
Pediatric Critical Care Nurse Practitioner
Pediatric Intensive Care Unit
Stead Family Children's Hospital
The University of Iowa Hospitals and Clinics
Iowa City, Iowa

Eliza Buyers, MD

Pediatric and Adolescent Gynecology
Children's Hospital Colorado
Assistant Professor
Department of Obstetrics and Gynecology
University of Colorado
Aurora, Colorado

Donald L. Chi, DDS, PhD

Professor
Oral Health Sciences
University of Washington School of Dentistry
Professor
Health Systems and Population Health
University of Washington School of Public Health
Seattle, Washington

Hana Conlon, BSN, MSN, CPNP

Nurse Practitioner
Columbia University Irving Medical Center
New York, New York

Daniel Crawford, DNP, ARNP, CPNP-PC, CNE, FAANP

Clinical Associate Professor
College of Nursing
The University of Iowa
Iowa City, Iowa

Sandra Daack-Hirsch, PhD, RN, FAAN

Professor
College of Nursing
The University of Iowa
Iowa City, Iowa

Renée L. Davis, DNP, APRN, CPNP-PC

Associate Professor, Traditional BSN Coordinator, Level II
Trudy Busch Valentine School of Nursing
Saint Louis University
St. Louis, Missouri;
Dr. Norman Pediatrics
Belleville, Illinois

Sara D. DeGolier, MS, RN, CPNP AC/PC

Pediatric Intensive Care Unit
Children's Hospital Colorado
Aurora, Colorado

Anne L. Derouin, DNP, APRN, CPNP, PMHS, FAANP

Assistant Dean, MSN Program
Clinical Professor
Duke Community and Family Medicine
Duke Global Health Institute
Duke University
Durham, North Carolina

Mary Dirks, DNP, RN, ARNP, CPNP-PC, FAANP, ELAN Fellow

Clinical Professor
College of Nursing
The University of Iowa
Iowa City, Iowa

Martha Driessnack, PhD, RN, PNP

Emerita Faculty
School of Nursing
Oregon Health & Science University
Portland, Oregon

Karen G. Duderstadt, PhD, RN, CPNP-PC, FAAN

Clinical Professor Emerita
Department of Family Health Care Nursing
School of Nursing
University of California San Francisco
San Francisco, California

Martha G. Fuller, PhD, RN, PPCNP-BC

Associate Professor of Nursing
University of San Diego
Nurse Practitioner
Developmental Services
Rady Children's Hospital
San Diego, California

Dawn Lee Garzon, PhD, CPNP-PC, PMHS, FAANP, FAAN

Nurse Practitioner
Department of Child and Adolescent Psychiatry
Washington University School of Medicine
St. Louis, Missouri

Nan M. Gaylord, PhD, RN, CPNP-PC, PMHS, FAANP, FAAN

Professor
College of Nursing
University of Tennessee
Knoxville, Tennessee

Valerie Griffin, DNP, PPCNP-BC, FNP-BC, PMHS, FAANP

Associate Professor, Director NP Specializations
School of Nursing
Southern Illinois University Edwardsville
Edwardsville, Illinois

Beth Heuer, DNP, CRNP, CPNP-PC, PMHS

Associate Professor of Clinical Instruction
Department of Nursing
College of Public Health
Temple University
Aston, Pennsylvania

Gail A. Hornor, DNP, CPNP, SANE-P

Forensic Nursing Specialist, Education
International Association of Forensic Nurses
Elkridge, Maryland

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP

Clinical Assistant Professor
Parent Child Health
Stony Brook University School of Nursing
Stony Brook, New York;
Nurse Consultant
Immunize.org
St. Paul, Minnesota;
Owner/Nurse Practitioner
Pediatric Nurse Practitioner House Calls
Massapequa Park, New York

Tasha Lowery, MSN, FNP-C, ENP-C, CPNP-AC

Assistant Professor, APRN Programs
Azusa Pacific University
Azusa, California;
Nurse Practitioner, CARES Center
General Pediatrics
Children's Hospital of Los Angeles
Los Angeles, California

Jennifer Newcombe, DNP, MSN, BSN

Nurse Practitioner
Pediatric Cardiothoracic Surgery
Loma Linda Children's Hospital
Assistant Professor
Loma Linda School of Nursing
Loma Linda, California

Katherine M. Newnam, PhD, CPNP-PC, NNP-BC, FAAN, FAANP

Associate Professor
College of Nursing
University of Tennessee
Knoxville, Tennessee

Sarah Obermeyer, PhD, CNM, WHNP, IBCLC, CNE

Associate Professor
Nurse Midwifery and Women's Health
Frontier Nursing University
Versailles, Kentucky;
Certified Nurse Midwife
Women's Health Center
Eisner Pediatric and Family Medicinal Center
Los Angeles, California

Adebola M. Olarewaju, PhD, MS

Pediatric Nurse Practitioner
Otolaryngology–Head and Neck Surgery
University of California Davis Health
Sacramento, California

Jaime Panton, DNP, CPNP-AC/PC

Associate Professor
School of Nursing
Columbia University
New York, New York

Jessica Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN

Clinical Professor
Louise Herrington School of Nursing
Baylor University
Dallas, Texas;
Past President
National Association of Pediatric Nurse Practitioners
New York, New York

Michele L. Polfuss, PhD, RN, APNP-AC/PC, FAAN

Professor, College of Nursing
University of Wisconsin–Milwaukee
Joint Research Chair in the Nursing of Children
Nursing Research and Evidence-Based Practice
Children's Wisconsin
Milwaukee, Wisconsin

Leslie N. Rhodes, DNP, PPCNP-BC

Pediatric Nurse Practitioner
Orthopaedics
Le Bonheur Children's Hospital
Assistant Professor
College of Nursing, Health Promotion and Disease Prevention
University of Tennessee Health Science Center
Memphis, Tennessee

Deanna Schneider, DNP, CPNP-PC/AC

Assistant Professor
Pediatric Nurse Practitioner Program
Columbia University School of Nursing
New York, New York

Danielle Sebbens, DNP, CPNP-AC/PC

Associate Director DNP Program
Associate Professor
Coordinator Acute Care Pediatric Nurse Practitioner Program
Edson College of Nursing and Health Innovation
Arizona State University
Pediatric Critical Care Nurse Practitioner
Pediatric Intensive Care Unit
Phoenix Children's Hospital
Phoenix, Arizona

Jennifer Sonney, PhD, APRN, PPCNP-BC, FAANP, FAAN

Joanne Montgomery Endowed Professor
Child, Family, and Population Health Nursing
University of Washington School of Nursing
Seattle, Washington

Jessica L. Spruit, DNP, RN, CPNP-AC, CPHON, BMTCN

Certified Pediatric Nurse Practitioner, Acute Care
Pediatric Palliative Care
Pediatric Blood and Marrow Transplant
C.S. Mott Children's Hospital
Ann Arbor, Michigan

Nancy Barber Starr, MS, RN, CPNP

Pediatric Nurse Practitioner
Advanced Pediatric Associates
Aurora, Colorado

We thank the previous edition contributors for their efforts in the Seventh Edition and whose work and ideas influenced this edition's content:

Sandra Ann Banta-Wright, PhD, RN, NNP-BC

Assistant Clinical Professor
Pediatric Nurse Practitioner Program
Oregon Health & Science University
Portland, Oregon

Jennifer Bevacqua, RN, MS, CPNP-AC, CPNP-PC

Instructor, Pediatric Nurse Practitioner
Program
Oregon Health & Science University
Portland, Oregon

Catherine G. Blosser, MPA, HA, RN, PNP

Pediatric Nurse Practitioner (Retired)
Multnomah County Health Department
Portland, Oregon

Cris Ann Bowman-Harvey, RN, MSN, CPNP-PC, CPNP-AC

Emergency Department
Children's Hospital Colorado
Aurora, Colorado;
Faculty, Department of Pediatrics
University of Colorado
Denver, Colorado

Helen N. Turner, DNP, APRN, PCNS-BC, AP-PMN, FAAN

Associate Professor
School of Nursing
Oregon Health & Science University
Portland, Oregon

Amber Wetherington, MSN, BSN, CPNP-PC

Pediatric Nurse Practitioner
Pediatric Urology
East Tennessee Children's Hospital
Knoxville, Tennessee

Lauren Siebrase-Wilkes, MSN, FNP-C

Advanced Practice Provider Supervisor
Co-Director, New Onset Seizure Clinic
Department of Pediatrics
The University of Iowa
Iowa City, Iowa;
Managing Clinical Director
Chapter Aesthetics Studios
Coralville, Iowa

Teri Moser Woo, PhD, ARNP, CPNP-PC, FAANP

Professor and Director of Nursing
Department of Nursing
Saint Martin's University
Lacey, Washington;
ARNP, Pediatric Urgent Care
Mary Bridge Children's Hospital
Puyallup, Washington

Jennifer Chauvin, MA, BSN, RN-BC

DNP Candidate, College of Nursing
Washington State University, Vancouver
Vancouver, Washington

Cynthia M. Claytor, RN, MSN, PNP, FNP-C, CCRN

Faculty, Graduate Nursing
Azusa Pacific University
Azusa, California

Ardys Dunn, PhD, RN, PNP

Associate Professor Emeritus
University of Portland School of Nursing
Portland, Oregon;
Professor (Retired)
Samuel Merritt College School of Nursing
Oakland, California

Terea Giannetta, DNP, CPNP, FAANP

Chief Nurse Practitioner, Hematology
Valley Children's Hospital
Madera, California;
Professor Emeritus, School of Nursing
California State University, Fresno
Fresno, California

Emily Gutierrez, DNP, C-PNP, PMHS, IFM-CP

Practice Owner
Neuronutrition Associates
Austin, Texas;
Adjunct Faculty, School of Nursing
Johns Hopkins University
Baltimore, Texas

Susan Hines, RN, BSN, MSN, CPNP

Pediatric Pulmonary Medicine
Children's Hospital Colorado
Aurora, Colorado

Jennifer Michele Huson, MS, RN, CPNP, CNS

Nurse Practitioner
Pediatric Intensive Care
Children's Hospital Los Angeles
Los Angeles, California

Belinda James-Petersen, BS, MS, DNP, CPNP

Gastroenterology
Children's Hospital of The Kings Daughters
Norfolk, Virginia

Rita Marie M. John, EdD, DNP, CPNP, PMHS, FAANP

Associate Professor of Nursing at CUMC, PNP Program
Columbia University School of Nursing
Hillsborough, New Jersey

Victoria Keeton, PhD, RN, CPNP-PC, CNS

Assistant Professor
Betty Irene Moore School of Nursing
University of California Davis
Sacramento, California

Sharon Norman, DNP, RN, CPNP, CNS, CCRN

School of Nursing
Oregon Health & Science University
Randall Children's Hospital at Legacy Emanuel
Portland, Oregon

Catherine O'Keefe, DNP, CPNP-PC

Adjunct Associate Professor Emerita
College of Nursing
Creighton University
Omaha, Nebraska

Sarah Elizabeth Romer, DNP, FNP

Assistant Professor, Adolescent Medicine, Pediatrics
University of Colorado, Denver School of Medicine
Medical Director, BC4U Clinic
Children's Hospital Colorado
Aurora, Colorado

Ruth K. Rosenblum, DNP, RN, PNP-BC, CNS

Assistant Professor
School of Nursing
San Jose State University
San Jose, California

Susan K. Sanderson, DNP, MSN FNP

Assistant Professor of Pediatrics
University of Utah
Salt Lake City, Utah

Kathryn Schartz, BA, BSN, MSN

Pediatric Nurse Practitioner
General Academic Pediatrics
The Children's Mercy Hospital
Kansas City, Missouri

Alan T. Schultz, MSN, CPNP

Pediatric Nurse Practitioner
Pediatric, Adolescent, and Young Adult Section
Joslin Diabetes Center
Boston, Massachusetts

Isabelle Soulé, PhD, RN

Human Resources for Health Rwanda
University of Maryland
Baltimore, Maryland

Asma Ali Taha, PhD, RN, CPNP-PC/AC, PCNS-BC, CCRN

Professor and Director
Pediatric Nurse Practitioner Program
School of Nursing
Oregon Health & Science University
Doernbecher Children's Hospital
Portland, Oregon

Becky Whittemore, MN, MPH, BSN

Nurse Practitioner
Metabolic Clinic
Oregon Health & Science University
Portland, Oregon

Elizabeth Willer, BA, BSN, MSN

Pediatric Nurse Practitioner (Retired)
Kaiser Permanente
Walnut Creek, California

Robert J. Yetman, MD

Professor of Pediatrics
Director of Division of Community and General Pediatrics
University of Texas Houston Medical School
Houston, Texas

Reviewers

Jacqueline Costello, DNP, MSN Ed, APRN, CPNP-PC

Advanced Practice Provider
Brody School of Medicine
East Carolina University
Greenville, North Carolina

Patricia Dempsey, DNP, APN-BC, PPCNP-BC

Adjunct Faculty
Monmouth University
West Long Branch, New Jersey

Jennifer Klimek-Yingling, PhD, RN, FNP-BC

Associate Professor of Nursing
Utica College
Utica, New York

Laura Roettger, BS, MS, PhD, APRN, CPNP-PC

Assistant Professor
Director of the Pediatric Nurse Practitioner Program
Thomas Jefferson University College of Nursing
Philadelphia, Pennsylvania;
Pediatric Nurse Practitioner
CompleteCare Health Network
New Jersey

This page intentionally left blank

Preface

We are delighted to introduce the eighth edition of *Burns' Pediatric Primary Care*. Maintaining the clinical relevancy of a book of this size requires frequent updates and intentional thought about how pediatric primary care practice evolves in an ever-changing health-care environment. We reorganized content into three distinct units: health promotion, health supervision, and disease management. The editorial team consists of actively practicing pediatric nurse practitioners who understand the challenges of practicing in post-pandemic healthcare settings and the increasing complexities and responsibilities placed on the primary care healthcare system. This text's success over the last two decades is largely attributable to the contributions of the chapter authors, each of whom is an expert in their field and actively is in their specialty and actively relevant for contemporary clinicians.

Burns' Pediatric Primary Care is a complete reference for anyone who provides primary care to infants, children, and adolescents. Pediatric nurse practitioners (PNPs) and family nurse practitioners (FNPs) are the primary audiences for this textbook. However, physicians, physician assistants, and nurses who care for children in a variety of settings also find this book to be a valuable resource. The textbook emphasizes health promotion, disease prevention, and problem management from the primary care provider's point of view. Each chapter introduces key concepts and provides an evidence-based and theoretical care foundation. Content is designed to allow experienced clinicians to easily navigate or jump to the topic or diagnosis in question, while the novice clinician or learner can read the entire chapter for immersion into the topic. Additional resources for each chapter include websites to access organizations and printed materials that may be useful for clinicians and their patients and families.

Special Features of the Eighth Edition

Some features of the eighth edition about which we are particularly excited include:

- Content reorganization that aligns our health supervision section with Bright Futures¹ and other national health guidelines. We made this change to reflect the current understanding of the continuum of health and illness and to ensure that the flow and classification of information are intuitive to students and providers.
- An introductory **Pediatric Primary Care** chapter helps set the tone for the book, focusing on the role of and influences on pediatric primary care.
- The **Global and National Influences on Child Health Status** chapter highlights selected topics, including adverse childhood experiences (ACEs) and the global effects of the COVID-19 pandemic.
- The **Environmental Influences on Pediatric Health** chapter focuses on the effects of climate change and its impact on health, as well as pediatric social, cultural, and physical environments. The chapter was redesigned to have less emphasis on specific environmental toxins.

- The **NEW Justice, Equity, Inclusion, and Diversity** chapter is completely redesigned to reflect a contemporary understanding of the roles of inequity and racism and their impact on pediatric health care and outcomes.
- The **Sexuality and Gender Identity** chapter was modified to include a discussion of gender identity and an expanded discussion of lesbian, gay, bisexual, transgender, queer, intersex, and asexual (LGBTQIA+) health.
- A **NEW Child Maltreatment** chapter, separating this content from the Injury Prevention chapter to emphasize the importance of its diagnosis and management in pediatric care.
- The impact of the COVID-19 pandemic on child physical and mental health was incorporated throughout the text, and the **Immunizations** chapter was updated with information about novel immunization technologies pioneered to develop the COVID-19 vaccines.
- The **Prescribing Traditional and Complementary Therapies** chapter is restructured with evidence-based treatments most likely to be helpful for the pediatric primary care provider.
- A **NEW Pediatric Palliative Care** chapter. This subspecialty has grown substantially in the last 2 to 3 years, and the chapter serves as a guide for primary care providers who manage and provide care coordination for pediatric patients at the end of life or who need palliative care.

Organization of the Book

Infants, children, and adolescents are a unique population. Pediatric primary healthcare requires unique perspective grounded in a fundamental understanding of the complexities of pediatric development, unique epidemiologic health influences, varied social determinants and environmental influences of health, and each child's unique genetic influences. These themes are incorporated throughout this book, along with the influence of telehealth and nontraditional appointment types in primary care.

The book is now reorganized into three units: Pediatric Primary Care, Pediatric Health Supervision, and Pediatric Diseases and Disorders. Unit I, Pediatric Primary Care, provides an overview of pediatric health care and influences that affect child health. Unit II, Pediatric Health Supervision, begins with overviews of pediatric/family assessment, behavioral/mental health, and sexuality/gender identity, followed by three subsections: Growth and Development, Health Promotion, and Health Protection. Unit III, Pediatric Diseases and Disorders, has two subsections: General Management and Specific Management. Special care was taken to ensure each chapter has the same organizational format to assist readers in locating information in busy clinical settings. Standards and guidelines for care are clearly identified, relevant child development is described, the physiologic and assessment parameters are discussed, management strategies are identified,

and the management of common problems is presented in a problem-oriented format. The scope of practice of the primary care provider is emphasized with appropriate referral and consultation strategies identified.

It is our hope that this book continues in the tradition of the prior editions. It is our aim to support the primary care provider with the highest quality, evidence-based care strategies and foster improved health and wellness of pediatric patients and their families.

Reference

¹Hagan JF, Shaw JS, Duncan PM. *Bright Futures: Guidelines for Health Supervision of Infants, Children and Adolescents*. 4th ed. American Academy of Pediatrics; 2017.

Acknowledgments

A book of this size and complexity cannot be completed without considerable help—the work of the chapter authors who researched, wrote, and revised content; the various specialty expert consultations and reviews that critiqued drafts and provided important perspectives and guidance; and the essential technical support from those who managed the production of the manuscript and the final product. We are particularly grateful to Laura Selkirk, Carrie Stetz, and Sandra Clark at Elsevier for their tireless support and advocacy during the development of this book.

Our Thanks to Family and Friends

- To my amazing daughters, Rachel and Elizabeth, whom I admire and respect and who give my life meaning, you are my heroes; to my dearest friend, Michelle Lowe, who is my person and who always has my back; and to Amy DiMaggio, friends, and family for loving me and giving me wings. Gracias y bendiciones. *Dawn Lee Garzon*
- With sincere gratitude and love to my amazing husband Chuck for his endless support and understanding during the extended time dedicated toward work on this edition. To my family and friends for their steadfast love, support, and encouragement, particularly my children Taylor and Jack and grandson Henry, my pride, joy, and true blessings. *Mary Dirks*
- I dedicate this new edition to my family, as they have supported me and allowed time for me to write and edit. To my parents, who passed on during my involvement with the text but who always encouraged my professional endeavors and taught me the importance of family, good health, and love. To my children, who have tolerated my busyness and still choose health care professions for themselves while producing wonderful grandchildren. And, finally, to my husband, who encouraged my involvement and provided the time and space to write by assuming additional home responsibilities. My love and appreciation to all of you. *Nan Gaylord*
- To my children and their children and their children who, along with children everywhere, are the living messages we send to a time we will not see. Here's hoping we have done well by them. *Martha Driessnack*
- The health of our nation's children is our most important resource. My hope is that this edition will contribute to that critical mission of improving the health and well-being of our children and families. Further, to my ever-patient husband who has sustained and bolstered me through the work on this edition! *Karen Duderstadt*
- To my husband Theo for his constant love and support, and to our children, who give my life so much joy and meaning. To my mentors, who have guided me along my professional path, and to God, for opening life-changing doors. *Jaime Panton*
- My deepest gratitude to my favorite people on earth, my wife Tina and children Madison, Nolan, Kaitlin, and Calvin, for your support in this work and all that I do. I love you so much and am so glad that we get to do life together. To my parents, family, friends, and colleagues (past and present), thank you for all you have taught me and for making life a great adventure! *Dan Crawford*

This page intentionally left blank

Contents

Unit 1: Pediatric Primary Care

- 1 Pediatric Primary Care, 1**
Martha Driessnack
- 2 Global and National Influences on Child Health Status, 6**
Karen G. Duderstadt
- 3 Environmental Influences on Pediatric Health, 12**
Martha G. Fuller and Karen G. Duderstadt
- 4 Justice, Equity, Inclusion, and Diversity, 27**
Jaime Panton and Dawn Lee Garzon

Unit 2: Pediatric Health Supervision

- 5 Pediatric and Family Assessment, 31**
Martha Driessnack and Daniel Crawford
- 6 Behavioral and Mental Health Promotion, 38**
Dawn Lee Garzon and Nancy Barber Starr
- 7 Sexuality and Gender Identity, 70**
Mary Dirks

Section 2A: Growth and Development

- 8 Developmental Principles and Theories, 83**
Martha Driessnack and Daniel Crawford
- 9 Developmental Management of Newborns and Neonates, 91**
Nan M. Gaylord and Katherine M. Newnam
- 10 Developmental Management of Infants, 103**
Mary Dirks
- 11 Developmental Management of Early Childhood, 120**
Valerie Griffin
- 12 Developmental Management of Middle Childhood, 139**
Jennifer Sonney

13 Developmental Management of Adolescents, 153

Jaime E. Panton

Section 2B: Health Promotion

- 14 Nutrition, 171**
Britta G. Beblavi
- 15 Breastfeeding, 190**
Sarah Obermeyer
- 16 Sleep, 206**
Anne Derouin
- 17 Elimination, 216**
Mary Dirks
- 18 Physical Activity and Sports, 231**
Michele L. Polfuss and Renée L. Davis

Section 2C: Health Protection

- 19 Immunizations, 265**
Mary Koslap-Petraco
- 20 Dental and Oral Health, 283**
Donald L. Chi
- 21 Pediatric Injury Prevention, 299**
Jaime Panton and Dawn Lee Garzon
- 22 Child Maltreatment, 306**
Gail A. Hornor

Unit 3: Disease Management

Section 3A: General Management Principles

- 23 Prescribing Traditional and Complementary Therapies, 320**
Jessica L. Spruit
- 24 Pediatric Pain and Fever Management, 329**
Helen N. Turner and Jaime Panton
- 25 Pediatric Injuries and Toxic Exposures, 345**
Sara D. DeGolia

26 Pediatric Palliative Care, 365*Deanna Schneider***Section 3B: Disease Management**

27 Congenital and Inherited Disorders, 376*Martha Driessnack and Sandra Daack-Hirsch***28 Neonatal Disorders, 395***Katherine Newnam and Nan M. Gaylord***29 Neurodivergence and Behavioral and Mental Health Disorders, 419***Dawn Lee Garzon and Nancy Barber Starr***30 Eye and Vision Disorders, 456***Teri Moser Woo***31 Ear and Hearing Disorders, 485***Adebola M. Olarewaju***32 Respiratory Disorders, 503***Jennifer Sonney and Jessica Peck***33 Cardiovascular Disorders, 536***Jennifer Newcombe***34 Gastrointestinal Disorders, 566***Danielle Sebbens***35 Infectious Diseases, 610***Andrea Achenbach, Jodi Bloxham, and Nan M. Gaylord***36 Inflammatory Disorders, 659***Tasha Lowery and Hana Conlon***37 Dermatologic Disorders, 709***Tami B. Bland***38 Hematologic Disorders, 767***Deanna Schneider***39 Endocrine and Metabolic Disorders, 799***Beth Heuer***40 Musculoskeletal Disorders, 841***Leslie N. Rhodes***41 Neurologic Disorders, 874***Daniel Crawford and Lauren Siebrase-Wilkes***42 Genitourinary Disorders, 908***Amber Wetherington***43 Gynecology and Reproductive Health, 934***Eliza Buyers***Appendix, 968****Index, 971**

1

Pediatric Primary Care

MARTHA DRIESSNACK



This chapter provides a brief review of the history and core concepts of pediatric primary care, including health promotion and protection, disease and/or disability prevention, the pediatric medical home, and the distinction between primary care versus prevention. It also draws attention to some of the many unique challenges in pediatrics, including caring for a two-generation or dual patient (parent/child), the importance of early influences and protective factors, children and youth with special healthcare needs, and facilitating transitions within/across pediatric healthcare specialists and from pediatric to adult health care. The chapter concludes by introducing Bright Futures, a national health promotion and preventive care initiative from the American Academy of Pediatrics (AAP), along with a list of other professional resources for pediatric primary care providers (PCPs). Subsequent chapters focus on global, national, and local issues; environmental influences; justice, equity, diversity, and inclusion; behavioral mental health promotion; and sexuality amidst emerging gender identity.

Pediatric Primary Care

Primary care represents one level of care within the larger health system. Subsequent levels of healthcare involve increased complexity, additional specialists, and specialized equipment. Accordingly, *primary* care is generalist care; *secondary* care requires specialized expertise; *tertiary* care requires both specialized expertise and equipment; and *quaternary* care requires highly specialized expertise and highly unusual or specialized equipment. Primary care is not site specific; however, it is often incorrectly used synonymously with *outpatient* or ambulatory care, while subsequent levels of care are typically associated with *inpatient* or acute care.

Primary care is conceptualized as being more *person* rather than *disease* centered and makes prevention as important as cure by addressing the root causes of poor health and focusing on threats to health. It includes the provision of continuous, relationship-oriented care over time, rather than being a series of limited disease-based interactions. Pediatric primary care serves as the primary interface between the child/family and the health system, except in the case of serious emergencies. The emphasis is on health promotion and protection, and disease and/or disability prevention. It is designed to be a first contact point, not simply a point of entry into the health system, and the “hub” of coordination (Fig. 1.1). In this central position, the PCP provides continuity as well as integrates subsequent or specialty care, regardless of where the care is delivered and who provides it. Decades of experience tell us that primary healthcare produces better outcomes, at lower costs, and with higher user satisfaction.^{1,2} Because it is comprehensive,

continuous, and person-centered care, primary care is also the ideal place for the establishment of the medical home.

The pediatric *medical home* is a care model that delivers patient- and family-centered care, coordinated, and tracked by a PCP within a community-based system, or *medical neighborhood*.


The AAP introduced the medical home concept over 50 years ago as a central location for archiving a child’s medical record. In its 2002 policy statement (<https://publications.aap.org/pediatrics/article-abstract/110/1/184/64107/The-Medical-Home?redirectedFrom=fulltext>), the AAP expanded the medical home concept to include operational characteristics, such as accessible, continuous, comprehensive, family-centered, coordinated, compassionate, and culturally effective care. At the core of the medical home is the PCP whose provision of high-quality, developmentally appropriate healthcare services needs to continue uninterrupted as the child moves within/across the healthcare system and later when transitioning from pediatric to adult care.

Primary Care Versus Primary Prevention


While primary care represents one of four levels of *care* within the larger health system, these levels are sometimes confused with levels of [disease] *prevention*. Disease prevention covers measures that not only prevent the occurrence of disease, but also arrest its progress and reduce its consequences once established. Preventive measures can be applied at any stage along the natural history of a disease, with the goal of preventing further progression of the condition. First described by Leavell and Clark,³ primary, secondary, and tertiary levels of prevention are best understood in terms of the natural history of disease (Fig. 1.2).

All healthcare providers aim to favorably influence the natural history of disease, but the anticipatory preventive actions they take differ based on the disease, disease stage, and the provider’s role in the health system. Preventive care is an important task that is assigned principally to PCPs.

Primary prevention includes efforts that keep disease processes from becoming established by either eliminating the causes or increasing individual resistance to disease. Preventive actions are taken before the onset of disease to remove the possibility that a disease ever occurs. There are two subcategories in primary prevention: (1) health promotion and (2) specific protection. *Health promotion* involves health maintenance and education efforts, including lifestyle changes/choices, nutrition, and maintenance of safe environments. *Specific protection* involves actions targeted at specific diseases, such as immunizations, antimalarial prophylaxis, and environmental modifications (such as fluoride).



• **Fig 1.1** Primary Care as a Hub of Coordination: Networking Within the Community Served and With Outside Partners. (From Van Lerberghe W. *World Health Organization. Primary Health Care: Now More Than Ever*. World Health Organization; 2008: 55.)



• **Fig 1.2** The Natural History of Disease Aligned With Levels of Prevention. (From Health Beyond Hospitals. Lecture for Ramathibodi Clinical Fellows. <https://www.slideshare.net/nawanon/health-beyond-hospitals-lecture-for-ramathibodi-clinical-fellows/>.)

Secondary prevention involves early diagnosis and prompt treatment, focusing on efforts that interrupt the disease process before it becomes symptomatic or halting the disease process at its incipient stage to prevent complications. The goal of secondary prevention efforts, including screening, early detection, and prompt treatment, is to cure the disease at the earliest stage, delay disease onset and/or duration, and reduce or reverse the transmission of disease.

Tertiary prevention efforts limit the physical and social consequences of symptomatic disease. The goal is to improve survival

and/or quality of life. As with primary prevention, there are two subcategories: (1) disability limitation and (2) rehabilitation. *Disability limitation* focuses on early symptomatic disease and includes measures aimed at correcting the anatomic and/or physiologic components of disease, thus preventing or limiting the impairment or disability caused by the disease. *Rehabilitation* focuses on late symptomatic disease. The goal is to mitigate the ultimate effects of the disease by preventing total social and/or functional disability or by restoring persons with disabilities to a self-sufficient role in society through psychosocial, medical, and/or vocational services.

Pediatric Primary Care Providers

There are several different pediatric PCPs, including pediatric and family nurse practitioners, pediatric and family physicians, and physician assistants. All are important and all are needed. It has been almost 10 years since the Children's Health Fund (CHF) shared that more than 20 million children (~28%) in the United States lacked sufficient access to essential healthcare. These statistics have only worsened as the CHF recently (2022) reported a 40% decrease in health screenings and a 44% decrease in outpatient mental health (see <https://www.childrenshealthfund.org/covid-19-has-kept-kids-from-primary-care/>). The fact that so many children are not receiving the care they need is a call to action for all who care for children.

Not only does failing to address healthcare access barriers threaten and undermine the health and wellbeing of children, but it also may have a direct impact on a child's ability to succeed academically and enter the workforce at their full potential. Loss of later productivity and the extraordinary costs of remediation will clearly have deleterious consequences for the future economic strength and vibrancy of the United States. The stakes could not be higher.⁴

This call to action is particularly timely as pediatric health concerns take on new issues and importance. For example, gun violence became the leading cause of death of youth under age 20 in the United States in 2020, surpassing deaths from car accidents, cancer, and even COVID-19 (see <https://www.childrenshealthfund.org/a-public-health-crisis-gun-violence-and-child-health-and-well-being/>).

Pediatric Nurse Practitioners Then and Now

In 1965 Dr. Loretta Ford and Dr. Henry Silver started the nation's first nurse practitioner (NP) program at the University of Colorado. As a result, Dr. Ford is often referred to as the mother of the NP movement and remains one of its greatest champions. One important piece of history is that this first NP program was pediatric, and its focus was on primary care. The emphasis in those early years was to expand public health nurses' roles, integrating the traditional role of the nurse with advanced training and authority in the delivery of primary care to children and families. This early focus on health promotion, protection, and disease prevention remains the mainstay of primary care pediatric nurse practitioner (PNP) programs across the country.

Today, the PNP role continues to evolve. The key difference between a primary care PNP and an acute care PNP is not the site where they practice, but the acuity of the patient for whom they are caring.⁵ Primary care PNPs, much like those in the early days with Dr. Ford, provide primary care, which includes well-child care and the prevention and/or management of both common pediatric acute illnesses and chronic conditions. In contrast, acute care PNPs provide care for acutely, critically, and chronically ill children who are unstable, experiencing life-threatening illness, are medically fragile, and/or are technologically dependent.

Unique Issues in Pediatrics

In this section, some of unique issues in pediatrics are introduced along with the inherent challenges that accompany them.

The Two-Generation or Dual Patient

One of the unique challenges in pediatrics is the two-generation or dual patient. Although the primary focus in pediatrics is the

patient, each pediatric patient comes with at least one parent or caregiver, if not three or four. Taking the time to understand and work with parents is essential to caring for the child; however, there are some distinctions with patient- and family-centered care (PFCC) and shared decision-making that are unique to pediatrics. When providing PFCC in adult care, providers acknowledge that it is the patient who has ultimate control over health-related decisions, while also knowing these decisions are contextualized within each patient's broader life experiences and family (see [Chapter 5](#)). The challenge of using a PFCC model in pediatrics is that there is not one patient, but two, and while the child is the focus, the parent is considered the authority in terms of decisions. For pediatric PCPs, one of the ongoing challenges is how to access, acknowledge, and include the child's voice in care decisions, as it is often lost and/or overridden in health care.

This ongoing tendency to lose track of children's voices is rooted in the long-standing tradition of looking at children across the pediatric lifespan through a deficit-based or developmental lens (see [Chapter 8](#)). For example, when it comes to children and adolescents, there is a presumption of decisional incapacity and therefore deference to parental authority. In contrast, adult patients get a presumption of decisional capacity, with familial insight serving only as adjunctive. While most parents make decisions in the best interests of their children most of the time, balancing the needs and wishes within the context of the dual patient can create difficult and challenging care decisions, especially as children's cognitive and executive function mature. Children's needs, and more often their wishes, do not take priority, especially when they differ from their parents. While parents are clearly authorities and caregivers, they are not complete surrogates. PCPs need to remember that, ultimately, they are the child's advocate and need to seek out their voices, actively engaging them in care and health-related decision making, and work to ensure that their voices are heard.

Lifelong Impact of Protective and Adverse Childhood Experiences

Science continues to highlight that early exposure to protective and adverse experiences can promote or disrupt healthy development. This awareness is fueling a new way of looking at life itself, not as disconnected stages, but as an integrated process across time. This *life course perspective* highlights that an individual's physical, mental, socioemotional, and spiritual health results from multiple risk and protective factors that operate throughout the lifespan, and the impact of those factors varies based on the life stage and context.⁶ As the science continues to develop, the scope of adverse experiences is evolving to include new factors (e.g., racism, weight stigma). It also focuses attention on the long-term effect of health-related interventions, such as the danger of ionizing radiation exposure from diagnostic medical radiation. *Image Gently* is a long-standing campaign to reduce pediatric risk for cancer during adulthood by increasing awareness and advocating for the protection of children from unnecessary radiation.⁷

In other words, what happens in childhood does not stay in childhood.⁸ Instead, what children experience in their earliest days and years of life shapes and defines their future, as early experiences shape the architecture of the developing brain and lay a foundation for long-term health (See Professional Resources, Center for the Developing Child). The World Health Organization (WHO), World Bank, and the United Nations International Children's Emergency Fund (UNICEF) have all drawn attention to the First 1000 Days of Life

(<https://www.unicef-irc.org/article/958-the-first-1000-days-of-life-the-brains-window-of-opportunity.html>) as the brain's "window of opportunity" or unique period when the foundations of health, growth, and neurodevelopment across the life span are established. Equally intriguing is the science behind Developmental Origins of Health and Disease (DOHaD), which suggests that harmful exposures early in life may increase the risk of disease (e.g., obesity, type 2 diabetes, insulin resistance, asthma, cardiovascular diseases, behavioral disorders, neurodegenerative diseases, reproductive disorders, some cancers) later in life.⁹ Further, some of these risks carry over into future generations. The link between early-life environmental factors and later-life disease was originally called the *Barker hypothesis*, a proposal that low birth weight predisposes to higher death rates in adult life.¹⁰

British epidemiologist David Barker's early work highlighting the influences of adverse events that occur during early phases of human development on the patterns of an individual's health and disease throughout life provided the foundation for the identification and study of adverse childhood experiences (ACEs). ACEs are linked to risky health behaviors (e.g., smoking, alcohol use, drug use), chronic health conditions (e.g., obesity, diabetes, depression, heart disease, cancer, stroke, chronic obstructive pulmonary disease), low life potential (graduation rates, academic achievement, lost time from work), and early death (see <https://www.cdc.gov/violenceprevention/aces/>). As the number of ACEs increases, so does the risk for adverse outcomes, which highlights the call for all pediatric PCPs to screen for and identify adversity in early life (See Professional Resources, The Resilience Project). Paralleling the work on adverse experiences and exposures is the science that identifies and promotes protective factors and ensuring that children flourish despite adversity.⁸ At the core of this research is seeking out and ensuring that children are exposed to safe, stable, and nurturing relationships (SSNRs), which can buffer adversity and build resilience. These efforts are particularly evident in the attachment and biobehavioral catch-up (ABC) interventions being introduced in foster care.¹¹ The PCP is well positioned to seek out, assess, and support protective factors at each well-child visit.

One additional protective factor for PCPs to consider is children's exposure to nature and/or green space, as there is continuing evidence that shows a positive relationship between nature contact and children's health.¹² In his now classic book, *Last Child in the Woods*,¹³ Louv wrote about what he called *nature-deficit disorder*, citing studies looking at the benefits of nature and calling attention to the problems that can come from being too isolated from the natural world. PCPs need to continue to emphasize, and perhaps even write prescriptions, for children to go outside and play in nature, limit screen time, and read stories about nature (or have them read to them). At the same time, they need to advocate for equitable nature contact for children in neighborhoods, schools, and communities.¹²

Transition to Adult Care

One of the core responsibilities of pediatric PCPs is coordinating transitions in care within/across the healthcare system as well as preparing all youth for the smooth transition to adulthood, to being responsible for their own health and decisions, and to adult care.¹⁴ The transition from pediatric to adult primary care is critical for all children, but especially for children and youth with special healthcare needs and those with congenital and/or inherited conditions. As advances in neonatal and pediatric medicine continue to improve the prognosis for many childhood conditions,

transitioning care is increasingly identified as a critical process for ongoing wellbeing. The AAP and the National Center for Medical Home Implementation created practice-based quality improvement guidelines that include specific activities, decision points, and a clear timeline for transition planning, transfer, and integration into adult care.¹⁵

Caring for Children and Youth With Special Healthcare Needs

In the United States, the federal government maintains a special responsibility to serve children living with complex and chronic medical conditions beginning with the early "crippled children's programs," which then evolved with the establishment of the Title V Maternal and Child Health Services Block Grant program.¹⁶ More recently, the Health Resources and Services Administration's Maternal and Child Health Bureau (HRSA-MCHB) established the term Children and Youth With Special Health Care Needs (CYSHCN) as "those who have or are at increased risk for a chronic physical, developmental, behavioral, or emotional condition and who also require health and related services of a type or amount beyond that required by children generally," such as asthma, cerebral palsy, and inherited conditions.¹⁷ A subset of CYSHCN is children with medical complexity, a fraction of the overall CYSHCN population, that require the most intensive services including home nursing care, respite, and palliative care.¹⁸

The proportion of CYSHCN increased over the past few decades, creating new challenges for the healthcare system as their care spans inpatient, outpatient, and community-based settings. These children and youth make up a sizable, yet diverse, population. While the overall prevalence of CYSHCN is approximately 19% of the pediatric population, the majority (85.1%) of these families report their child's care is poorly coordinated.¹⁶ Also of note are the inequities experienced by CYSHCN and their families, particularly those in under-resourced communities.¹⁶ One effort to address these issues is the HRSA-MCHB Blueprint for Change,¹⁸ which identifies four critical, yet interconnected, areas: health equity, family and child wellbeing and quality of life, access to services, and financing of services. Addressing these critical areas requires a concerted, holistic, and integrated approach so that CYSHCN can enjoy a full life from childhood through adulthood; thrive in a system that supports their families and their social, health, and emotional needs; and be assured that their dignity, autonomy, independence, and active participation in their communities will be supported.¹⁸

The role of the PCP in the care of CYSHCN cannot be overstated, as these children and youth also require ongoing health maintenance, illness prevention, and developmental surveillance. As noted earlier, primary care is designed to be a first contact point, not simply a point of entry into the health system, and the "hub" of coordination (see Fig. 1.1). For CYSHCN, the PCP provides much needed continuity and coordination of care as these children and youth grow and develop. In this role, the PCP reviews subspecialty notes and recommendations, looks for areas of duplication or contradictions, and helps understand recommendations, treatments, and federal and state programs [e.g., Section 504 Plan, Individualize Education Plan (IEP)]. For some CYSHCN, an interdisciplinary specialty clinic (e.g., spina bifida) may be the preferred care coordinator, reaching out to the PCP as a consultant on primary care issues.

All families with a CYSHCN need to be prepared for acute and/or emergency care from those not familiar with their child's condition. The AAP and the American College of Emergency Physicians created an Emergency Information Form (EIF) that ensures a CYSHCN's complicated medical history, as well as special needs and/or considerations, are concisely summarized. This form can be used to transfer relevant information when the CYSHCN has an acute health problem and their parent, caregiver, or familiar PCP is not immediately available, as well as shared with unfamiliar emergency departments and/or personnel (e.g., EMS professionals). A downloadable version is available at: <https://www.acep.org/by-medical-focus/pediatrics/medical-forms/emergency-information-form-for-children-with-special-health-care-needs/>. Other resources for these families include:

- Centers for Medicare and Medicaid Services Forms: <https://www.cms.gov/Medicare/CMS-Forms/CMS-Forms/CMS-Forms-List.html>
- Child Care Aware: state-by-state resources. Includes childcare, health and social services, financial assistance, children with special needs, additional resources available in each US state. <https://www.childcareaware.org/resources/map/>
- Children and Youth with Special Health Care Needs (CYSHCN): <https://mchb.hrsa.gov/programs-impact/focus-areas/children-youth-special-health-care-needs-cyshcn>
- Family Voices: National Center for Family Professional Partnerships (NCFPP): www.fv-ncfpp.org
- Medical Home Portal: <https://www.medicalhomeportal.org/issue/writing-letters-of-medical-necessity>

Additional Resources

Bright Futures: Health Promotion and Preventive Care Initiative

While there are many resources for primary care, Bright Futures (<https://www.brightfutures.org/>) is a key resource for all pediatric PCPs. It provides theory-based and evidence-driven guidance for well-child care and preventive care screenings. The resource emphasizes the family as the child's primary source of strength and support and recognizes the importance of the child's and family's perspectives in clinical decision-making. This patient- and family-centered approach captures the importance of engaging both the family and the patient in a developmentally supportive manner as essential members of the primary healthcare team.

Bright Futures is led by the AAP and supported by the Maternal and Child Health Bureau, Health Resources and Services Administration (HRSA). It identifies 12 key health promotion themes, including healthy development, family support, mental health and emotional wellbeing, nutritional health, physical activity, healthy weight, lifelong health for families and communities, oral health, healthy adolescent development, safety and injury prevention, healthy and safe use of social media, and children and youth with special health needs. These themes align with the content of this textbook, providing a parallel resource for pediatric PCPs.

Other Resources for Primary Care Providers

- Bright Futures for Families: <https://familyvoices.org/projects/>
- Center for the Developing Child: <https://developingchild.harvard.edu/>
- National Resource Center for Patient/Family-Centered Medical Home: <https://www.aap.org/en/practice-management/medical-home/>
- The Resilience Project: <https://www.acesaware.org/resource/american-academy-of-pediatrics-the-resilience-project-related-aap-policy/>

References

1. Mold JW. How primary care produces better outcomes: a logic model. *Ann Fam Med*. 2014;12(5):483–484.
2. *Primary Health Care Measurement Framework and Indicators: Monitoring Health Systems through a Primary Care Lens*. Geneva: World Health Organization and the United Nations Children's Fund (UNICEF); 2022.
3. Leavell H, Clark AE. *Preventive Medicine for Doctors in the Community*. New York: McGraw-Hill; 1965.
4. Children's Health Fund Children's Health Fund. *Unfinished Business. 20 Million Children in U.S. Still Lack Sufficient Access to Essential Health Care*; 2016. <https://www.childrenshealthfund.org/advocacy-publications/>.
5. American Nurses Association. *Pediatric Nursing: Scope and Standards of Practice*. American Nurses Association; 2015.
6. Russ SA, Hotez E, Berghaus M, et al. Building a life course intervention research framework. *Pediatrics*. 2022;149(suppl 5).
7. Applegate KE, Cost NG. Image gently: a campaign to reduce children's and adolescents' risk for cancer during adulthood. *J Adolescent Health*. 2013;52(5 Suppl):S93–S97.
8. Garner A, Yogman M. Preventing childhood toxic stress: partnering with families and communities to promote relational health. *Pediatrics*. 2021;148(2):e2021052582.
9. Heindel JJ, Vandenberg LN. Developmental origins of health and disease: a paradigm for understanding disease cause and prevention. *Curr Opin Pediatr*. 2015;27(2):248–253.
10. Bianchi ME, Restrepo JM. Low birthweight as a risk factor for non-communicable diseases in adults. *Front Med (Lausanne)*. 2022;8:793990.
11. Grube WA, Liming KW. Attachment and biobehavioral catch-up: a systematic review. *Infant Ment Health J*. 2018;39(6):656–673.
12. Fyfe-Johnson AL, Hazlehurst MF, Perrins SP, et al. Nature and children's health: a systematic review. *Pediatrics*. 2021;148(4):e2020049155.
13. Louv R. *Last Child in the Woods*. Algonquin Books; 2008.
14. Davidson LF, Doyle MH. Healthcare transition: a vital part of care, growth, and change for pediatric patients. *Pediatr Rev*. 2021;42(12):684–693.
15. White PH, Cooley WC, Transitions Clinical Report Authoring Group; American Academy of Pediatrics; American Academy of Family Physicians; American College of Physicians. Supporting the health care transition from adolescence to adulthood in the medical home. *Pediatrics*. 2018;142(5):e20182587. Erratum in *Pediatrics*. 2019;143(2).
16. Ghandour RM, Hirai AH, Kenney MK. Children and youth with special health care needs: a profile. *Pediatrics*. 2022;149(suppl 7).
17. McPherson M, Arango P, Fox H, et al. A new definition of children with special health care needs. *Pediatrics*. 1998;102(1 Pt 1):137–140.
18. McLellan SE, Mann MY, Scott JA, Brown TW. A blueprint for change: guiding principles for a system of services for children and youth with special health care needs and their families. *Pediatrics*. 2022;149(suppl 7):e2021056150c.

2

Global and National Influences on Child Health Status

KAREN G. DUDERSTADT



The health of all children is interconnected worldwide, and each child's health must be viewed through a global lens. Whether considering pandemic infectious diseases or global migration, child health status inequities globally and nationally are largely determined by socioeconomic status, which affects overall pediatric health and child development. Biosocial circumstances, or social determinants of child health, are shaped by economics, social policies, politics, and climate change at local, regional, national, and global levels. This social health gradient that runs from the top to the bottom of the socioeconomic spectrum creates health inequities that affect low-, middle-, and high-income countries (HICs) disproportionately.

Significant global progress had been made to reduce childhood morbidity and mortality before the onset of the COVID-19 global pandemic. Although there was a low risk of severe illness or death in children who contracted COVID-19, the pandemic had a profound effect on the physical and mental health of the pediatric population nationally and globally.

This chapter presents an overview of the global health status of infants, children, and adolescents. It describes the effects of the COVID-19 pandemic on pediatric health, the impact of climate change on child health inequality, the progress towards achieving the United Nations (UN) Sustainable Development Goals (SDGs) and Healthy People 2030 targets, and the factors that affect child health in the United States, including food and housing insecurity. The chapter also discusses the important role pediatric primary care providers (PCPs) have in advocating for policies that foster health equity and access to quality healthcare services for all children and families.

COVID-19 and the Global Health Status of Children

The launch of the 2030 Agenda for the UN SDGs a decade ago heralded a period of dramatic improvements in most countries in maternal and child survival rates (Fig. 2.1). The global maternal mortality rate (MMR) declined 38% from 2000 to 2017 and the mortality rate for children younger than 5 years declined by more than half.¹ However, the global crises of the COVID-19

pandemic, climate change, and warring conflicts are all affecting the likelihood of reaching the 2030 SDGs.

The recent indicators for the 17 UN SDGs reflect the impact of a reversal of progress towards achieving improving maternal and child health status globally.² Findings include^{1,2}:

- The COVID-19 pandemic erased previous progress on poverty eradication and pushed 93 million more people into extreme poverty in 2020.
- Twenty-five percent of the global population lives in conflict-affected countries. A record 100 million people were forcibly displaced worldwide.
- More than 24 million learners from primary school to university are at risk of never returning to school.
- Childhood immunization coverage dropped for the first time in a decade, and a global rise in deaths from tuberculosis and malaria occurred. Coverage for the third dose of diphtheria-tetanus-pertussis (DTP) declined from 86% to 81% globally during the first 2 years of the pandemic.
- Global administration of the first dose of the human papillomavirus (HPV) vaccine declined from 20% (2019) to 15% (2021), leaving millions of adolescents at risk for cervical, genital, and oral cancers later in life.

Around 40% of the global population forcibly displaced worldwide are children, and this disruption to their lives and development results in adverse stress and childhood trauma, which is linked to later impairments in learning, behavior, and physical and mental wellbeing.³ Anxiety and depression among adolescents and young adults increased significantly during the pandemic, particularly in females, and highlighted the lack of available counseling and psychiatric services in health system structures globally and nationally.

Since the onset of the COVID-19 pandemic, international data regarding pediatric mortality were published and the recent UN Inter-Agency Group for Child Mortality Estimation (UNIGME) reported on data from 77 countries. This organization found that the youngest children were the least vulnerable to COVID-19 variants. UNIGME defines pediatric deaths as those that occur in individuals under the age of 24 years. Twenty-seven percent of the COVID-19 pediatric deaths occurred in children from birth to 9 years of age, while 42% occurred in youth 20 to 24 years of



• **Fig 2.1** United Nations Development Program (UNDP) Sustainable Development Goals (SDGs) for 2030. (From United Nations. *The Sustainable Development Goals Report 2022*. <https://www.un.org/sustainabledevelopment/>. The content of this publication has not been approved by the United Nations and does not reflect the views of the United Nations or its officials or Member States.)

age.⁴ Overall child mortality remains high, and the COVID-19 pandemic exacerbated the burden of pediatric loss of life. In 2020 alone, 5 million children died from all causes before reaching their third birthday.⁴ Children born in sub-Saharan Africa had the highest mortality rate at 74 deaths per 1000, 14 times higher than in the HICs. Sub-Saharan Africa has the highest rate of neonatal mortality at 27 per 1000 live births, followed by Southeastern Asia at 23 per 1000 live births.⁴ If the current trend continues, 54 countries will not meet the 2030 UN SDGs.

It became evident during the pandemic that the COVID-19 crisis was an extraordinary challenge for national statistical systems and a wake-up call for the need for stronger information and communication technology (ICT) infrastructure foundations.² It also became an opportunity for countries to experiment with innovative data collection methods, explore new data sources, and modernize ICT infrastructures to meet data demands for global and national policymaking to guide healthcare decisions.

In 2022 the UN General Assembly adopted a resolution that codified the human right to a clean, healthy, and sustainable environment on the 75th anniversary of the Universal Declaration of Human Rights.⁵ The confirmation of this human right gives global activists a new tool for advocacy on the effects of climate change and the loss of biodiversity. Reigniting optimism and collective action are required as the impact of the global pandemic eases to strengthen healthcare systems and social and political protective systems to create a more resilient and secure world for our children and families.¹

Pediatric Mortality Globally

The UN SDGs called for an end to preventable deaths of newborns and children under 5 years old, set the goal of a neonatal mortality rate of 12 or fewer deaths per 1000 live births and an under-5 years mortality rate of 25 or fewer deaths per 1000 live


births. However, 54 countries will not meet the under-5 mortality target by 2030, and 61 countries will miss the neonatal mortality target.⁴ Of further concern, neonatal and infant mortality remains highest in sub-Saharan Africa, Central Asia, and Southeast Asia.

About 43% of pediatric deaths globally occurred among those 5 to 24 years old. Although adolescent mortality declined by nearly 40% since 1990, almost 1 million adolescents died in 2020.⁴ Over 70% of all pediatric deaths occurred in sub-Saharan Africa (45%) and Central and Southern Asia (27%). The global pandemic contributed to a significant setback in recent progress on each of these health indicators.

Food Insecurity

Hunger and undernutrition are often associated with *food insecurity*, which exists when individuals, families, and/or whole populations do not have physical and economic access to sufficient, safe, nutritious, and culturally acceptable food to meet nutritional needs. Food insecurity may occur in impoverished populations in developing countries and in industrialized nations, particularly among immigrant populations. Children affected by migration and family separation are at the highest risk for food insecurity and are also vulnerable to adverse health consequences such as exposure to exploitation and child trafficking.

Growing evidence indicates the dramatic effect of climate change on food crop production and distribution issues globally and subsequent contributions to human migration patterns and food insecurity. Globally, undernutrition is an important determinant of maternal and child health and accounts for 45% of deaths in children younger than 5 years.⁶ Children who are exclusively breastfed for the first 6 months of life are 14 times more likely to survive than nonbreastfed infants, yet the lowest breastfeeding rates are in nations with the lowest per capita incomes.




• **Fig 2.2** Relationship Between Climate Change and Child Health Inequalities. (From Arpin E, Gauffin K, Kerr M, et al. Climate change and child health inequality: a review of reviews. *Int J Environ Res Public Health*. 2021;18[20]:10896.)

Climate Change and Global Child Health Inequality

Climate change is an urgent problem that impacts the global pediatric population disproportionately. Many children living in low- and middle-income countries (LMICs) lack the essential determinants of health, including clean air, adequate shelter, nutrition, safe water, and sanitation, which contributes to the higher risk of malnutrition and growth stunting. These factors are exacerbated by the direct and indirect effects of climate change, which include vector-, water-, and food-borne infectious diseases.⁷ Inequalities also exist within HICs, as many children in low-income households experience high levels of air pollution, food insecurity, and poor housing conditions (Fig. 2.2).⁷ Even with recent improvements in childhood survival rates in LMICs, the mortality rate of children under 5 years of age remains twice as high for children born in the poorest countries compared to the highest per-capita income countries.¹

The mental health of children and adolescents globally is impacted by immigration, social, and economic environments including loss of native lands due to crop failures resulting in food insecurities, exposure to violence, and disruption in learning and teaching as well as the COVID-19 pandemic (Fig. 2.3).⁸ The overall prevalence of pediatric posttraumatic stress (PTS) increased globally, with the highest prevalence in regions impacted by natural disasters. In a recent study in the United States, more than 80% of children 10 to 12 years of age revealed fear, sadness, and anger when discussing their feelings about environmental problems.⁸ As the pandemic eased, many 10- to 19-year-olds globally moved to environmental advocacy, despite adversity, and established “Fridays for Future” to put moral pressure on policymakers to take forceful action to address climate change (<https://friday-forfuture.org/>).

The recent Intergovernmental Panel on Climate Change (IPCC) Report illustrated the urgent need for interventions to mitigate the effects of climate change and echoed editorials published in 200 medical journals calling for urgent action to address



• **Fig 2.3** Effect of Climate Change and Mental Health Policy in Children and Adolescents. (From Clemens V, von Hirschhausen E, Fegert J. Report of the intergovernmental panel on climate change: implications for the mental health policy of children and adolescents in Europe—a scoping review. *Eur Child Adolesc Psychiatry*. 2022;31:701–713.)

climate change, restore biodiversity, and protect health.⁹ LMICs have limited capacity to mitigate the effects of climate change with current economic structures and prevailing political forces. Enhanced interventions by HICs are necessary to promote and fund mitigation and adaptation in LMICs to address climate change.⁷

Despite the recognition of the health-related inequities due to climate change, quantitative data are lacking on the direct consequences of extreme heat events, hurricanes, and subsequent flooding and infrastructure damage on child health outcomes.⁷ Global greenhouse gas emissions must decline 43% by 2030 to stave off the worst climate-related impacts.² Current national commitments

point to a nearly 14% increase by 2030, and greater engagement in policy action and behavior change is urgently needed to meet the 1.5°C target.²

Health Status of Children in the United States

The COVID-19 pandemic disrupted data collection for the key child health indicators—economic wellbeing, education, health, and family and community—resulting in some data in the latest report reflecting 2020 estimates. As a result, the child health indicators do not fully reflect the effect of the pandemic on children and families. In 2020 fewer children were living in poverty, with one in six children living in poor families.¹⁰ Massachusetts continues to rank first in overall child wellbeing, followed by New Hampshire and Minnesota. Three states including Mississippi (48th), Louisiana (49th), and New Mexico (50th) ranked the lowest nationally.¹⁰ Children living in the Southwest have the lowest rating in child wellbeing indicators. California ranks seventh in child health indicators but 45th in family economic wellbeing.¹⁰

The United States has significant gaps in educational achievement and graduation outcome by race and income among all pediatric age groups.¹⁰ High-school graduation rates dipped in 20 of 26 states reporting in 2021, ending two decades of national progress. Home confinement and learning remotely during the pandemic disrupted teaching and learning, with greater impacts seen among children and adolescents living in low-income families. Illinois, Oregon, and North Dakota dropped 2% in 2021.¹¹ In some counties in Nevada, graduation rates dropped 2.6% during the pandemic due to adolescents living in low-income families working longer hours and caring for younger siblings.¹¹ In Oregon and Nevada, the share of high-school freshmen who completed their last school year on track to graduate was about 10% lower than before the pandemic.¹¹ Students contending with mental health issues may not be able to focus in the classroom, fall behind in core areas such as math and reading, and often struggle to graduate.¹⁰

In December 2021 the US Surgeon General and leaders in pediatric health policy declared a child mental health emergency.¹² The 2019 National Survey on Drug Use report indicated in the year before the onset of the pandemic, 3.5 million adolescents had a major depressive episode, about one in seven youths aged 12 to 17 years (15.7%).¹³ Between March and October 2020, emergency department (ED) visits for mental health issues rose by 24% for children ages 5 to 11 years and 31% for those ages 12 to 17 years. Compared to the same period in 2019, in early 2021, ED visits for suspected suicide attempts increased by nearly 51% among girls ages 12 to 17 years.¹⁴ Suicidal behaviors increased among youth with 19% seriously considering suicide (33% increase from 2009 to 2019).¹⁵ Pediatric deaths nationally reflect increased suicide rates and include victims of gun violence, which surged ahead of motor vehicle deaths to become the leading cause of death for young people ages 1 to 19 years in 2020.¹⁵

The pandemic contributed significantly to the youth mental health crisis. More than 140,000 children in the United States lost a primary and/or secondary caregiver, with youth of color disproportionately impacted.¹⁶ This family crisis compounded the already increasing rates of depression, anxiety, trauma, loneliness, and suicidality among youth in the United States. The current challenges facing children and adolescents are so widespread that

urgent action is needed at all levels of government and by PCPs and advocates for children and adolescents for increased policy action nationally.¹²

Infant Mortality

Infant mortality in the United States remains higher than other HICs. The United States ranks 21st among the other higher per-capita income countries. In 2020 the overall infant mortality rate in the United States was 5.4 deaths per 1000 live births. Almost 20,000 infants died in the United States in 2020 from causes including preterm birth and low birth weight, birth defects, maternal pregnancy and neonatal complications, and sudden infant death syndrome (SIDS).¹⁷ Inequality in infant mortality rates remains, with Black infants having the highest mortality rate at 10.38 per 100,000, followed by Native American and Alaskan Native infants at 7.68 per 100,000. Hispanic infant mortality rates improved slightly in 2020 at 4.69 per 100,000 and non-Hispanic White infants at 4.40 per 100,000.¹⁸

Childhood Obesity

One of the most concerning pediatric health indicators is the percentage of overweight and obese children in the United States. In 2020 the prevalence of pediatric obesity was 19.7%, with about 14.7 million children and adolescents.¹⁹ Children gained weight at a faster rate during the pandemic compared to prepandemic, with younger school-aged children (6–11 years) experiencing a body mass index change rate that was 2.5 times higher than before the pandemic.²⁰ Schools contribute to obesity prevention efforts for school-aged youth by providing regularly scheduled opportunities for physical activity and offering nutritious foods through school meal programs. This approach does not single out students according to their weight status or body size but aims to support the health and wellbeing of all students. With the prevalence of pediatric obesity, there is a significant increase in the prevalence of type 2 diabetes, metabolic syndrome, and hypertension. Of all the pediatric health indicators, overweight and obesity significantly directly affect public health costs and the cost of providing health-care services nationally.

Food and Housing Insecurity

Despite many government food assistance programs in the United States, 10.2% (13.5 million) of US households were food insecure at some time during 2021.²¹ Children who are food insecure are more likely to have poor general health, higher hospitalization rates, experience more behavioral problems, and have increased incidence of overweight, asthma, and anemia. Factors other than income impact whether a household is food insecure. Lower maternal education, single-parent households, intimate partner violence, and parental substance abuse all contribute to food-insecure households. Maternal depression increases the likelihood that young children experience food insecurity by 23% to 79%, depending on enrollment in public programs, which play an important role in buffering the effects of food insecurity nationally.²²

Three-quarters of children spend some portion of their preschool years being cared for outside of the home. Depending on childcare arrangements, the care contributes to or ameliorates the effects of food insecurity for children. Those who attend a preschool or childcare center have lower food insecurity, whereas

children cared for at home by an unrelated adult are at higher risk for food insecurity. The Supplemental Nutritional Assistance Program (SNAP), the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), and the School Breakfast Program (SBP) are federally funded programs established to address childhood hunger. WIC provides an average of \$56.90 per participant per month for purchasing healthy food.²³ Recent WIC data indicate the proportion of infant formula distributed to enrollees declined during the pandemic, which may reflect the trends of increased rates of breastfeeding in the United States.

Children living in poverty are significantly affected by access to affordable housing, particularly immigrant children and families living in large metropolitan areas. The affordable housing crisis is one of the primary reasons so many families are homeless. Children made up 107,069—nearly one in five—of the nearly 568,000 people who were homeless on a single night in January 2019.²⁴ Although many children who are homeless are reportedly in shelter programs, experiencing this lack of family financial stability, the limited housing supply in inner cities, and the high eviction rates during the pandemic negatively combined to impact the education and physical and mental health of the children in these families.

Healthy People 2030

Healthy People (HP) 2030 is the fifth national initiative focused on improving healthcare services and health outcomes for children, adolescents, and families. The initiative monitors the national data trends on 23 specific leading health indicators (LHIs) on child and adolescent health status and includes foci specific to the social determinants of health and health-related quality of life objectives. The HP 2020 initiative met five of the target objectives in the LHIs²⁵:

- 36% of children aged 9 to 35 months were screened for autism spectrum disorder and other developmental delays in the past 12 months.
- 46% of children and adolescents accessed oral health care.
- 95% of children entering kindergarten had received two doses of MMR vaccine.
- Reduced the proportion of children who get no recommended vaccines by 2 years of age to less than 2%.
- Reduced the number of children who experience child abuse and neglect (8.4 per 1000 children).

Reporting on HP 2020 initiative found that progress declined in seven of the target areas, including²⁴:

- The percentage of fourth-grade students attending public and private schools with reading skills at or above their grade level fell to 35%.
- The proportion of children 6 to 13 years of age who have sufficient aerobic physical activity declined to 25.6%.
- The proportion of students participating in the School Breakfast Program declined to 21%.
- The rate of deaths in children and adolescents aged 1 to 19 years of age increased to 27.6 deaths per 1000.
- The percentage of children and adolescents under 18 years of age with special healthcare needs who received care in family-centered, comprehensive health care declined to 14%.

To meet the target objectives for HP 2030, strong advocacy is needed by PCPs and policymakers to move the national focus to improve healthcare and educational systems that better address the needs of children and adolescents to improve overall pediatric healthcare status.

Advocacy for Improved Child Health Status

Pediatric PCPs have a key role in advocating for child health locally, nationally, and globally. They provide continuity of care in the ambulatory care setting for underserved children with health conditions such as asthma, pneumonia, and vaccine-preventable conditions that might otherwise lead to greater use of costly emergency departments and hospitalizations. Increasing access to pediatric PCPs who deliver comprehensive primary care services reduces healthcare costs, improves health outcomes, and produces healthcare savings—all steps that would allow the United States to lead rather than trail the other economically developed countries in child health indicators. In addition, pediatric PCPs can advocate for children and influence economic and political decisions to ameliorate health disparities and increase health equality among populations and communities to build a healthier generation of adults. A sustained effort is required globally and nationally to build better health systems to continue to positively impact child health outcomes. The framework of the UN Millennium Development Goals and Healthy People 2030 goals sets the mark for improving child health status globally and nationally.

References

1. World Health Organization (WHO) and United Nations Children's Fund (UNICEF). *Protect the Promise: 2022 Progress Report on the Every Woman Every Child Global Strategy for Women's, Children's, and Adolescents' Health (2016–2030)*; 2022. <https://data.unicef.org/resources/protect-the-progress-every-woman-every-child-report-2022/#>.
2. United Nations (UN). *The Sustainable Development Goals Report; 2022*. <https://unstats.un.org/sdgs/report/2022/The-Sustainable-Development-Goals-Report-2022.pdf>.
3. Shonkoff J, Garner A, et al. The lifelong effects of early childhood adversity and toxic stress. *Pediatrics*. 2012;129(1):e232–e246.
4. United Nations Inter-Agency Group on Child Mortality Estimation (UNIGME). *Levels & Trends in Child Mortality: Report; 2021*. <https://www.who.int/publications/m/item/levels-and-trends-in-child-mortality-report-2021>.
5. United Nations Development Programme. UN General Assembly Resolution July 28th 2022. <https://news.un.org/en/story/2022/07/1123482>
6. World Health Organization (WHO). *Child Mortality (under 5 years)*; 2020. <https://www.who.int/news-room/fact-sheets/detail/levels-and-trends-in-child-under-5-mortality-in-2020>.
7. Arpin E, Gauffin K, Kerr M, et al. Climate change and child health inequality: a review of reviews. *Int J Environ Res Publ Health*. 2021;18(20):10896.
8. Clemens V, von Hirschhausen E, Fegert J. Report of the intergovernmental panel on climate change: implications for the mental health policy of children and adolescents in Europe—a scoping review. *Eur Child Adolesc Psychiatr*. 2022;31:701–713.
9. Masson-Delmotte V, Zhai P, Pirani A, et al. *Climate Change 2021: The Physical Science Basis*; 2021.
10. A.E. Casey Foundation. An annual report on how children are faring in the United States. The 2022 KIDS COUNT Data Book: State Trends in Child Well-Being. <https://assets.aecf.org/m/resourcedoc/aecf-2022kidscountdatabook-2022.pdf>.
11. Barnum M, Belsha K, Wilburn T. *Graduation Rates Dip across U.S. As Pandemic Stalls Progress*; 2022. <https://www.chalkbeat.org/2022/1/24/22895461/2021-graduation-rates-decrease-pandemic>.
12. American Academy of Pediatrics (AAP). *American Academy of Child and Adolescent Psychiatry (AACAP) AAoCaAP; Children's Hospital Network (CHN). A Declaration from the American Academy of*

- Pediatrics*. American Academy of Child and Adolescent Psychiatry and Children's Hospital Association; 2021. <https://www.aap.org/en/advocacy/child-and-adolescent-healthy-mental-development/aap-aacap-cha-declaration-of-a-national-emergency-in-child-and-adolescent-mental-health/>.
13. Substance Abuse and Mental Health Services Administration. *Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health*; 2020. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP20-07-01-001-PDF.pdf.
 14. Leeb R, Bitsko R, Radhakrishnan L, et al. Mental health-related emergency department visits among children aged <18 years during the COVID-19 pandemic—United States, January 1–October 17. *Morb Mortal Wkly Rep*. 2020;69:1675–1680.
 15. Centers for Disease Prevention and Control. Youth risk behavior survey data: Summary and trend Reports 2009-2019. <https://www.cdc.gov/healthyyouth/data/yrbs/>.
 16. Hillis S, Blenkinsop A, Villaveces A, et al. COVID-19–Associated orphanhood and caregiver death in the United States. *Pediatrics*. 2021;148(6):31–43.
 17. Center for Disease Prevention and Control. Infant Mortality. <https://www.cdc.gov/reproductivehealth/maternalinfanthealth/infantmortality.htm>.
 18. Ely D, Driscoll A. Infant mortality in the United States, 2020: data from the period linked birth/infant death file. *Natl Vital Stat Rep*. 2022;71(5):1–18.
 19. Center for Disease Prevention and Control. Prevalence of Childhood Obesity in the United States. <https://www.cdc.gov/obesity/data/childhood.html>.
 20. Center for Disease Prevention and Control. Obesity. <https://www.cdc.gov/healthyschools/obesity/>.
 21. US Department of Agriculture. Food Insecurity in the U.S. <https://www.ers.usda.gov/topics/food-nutrition-assistance/food-security-in-the-u-s/key-statistics-graphics/>.
 22. Noonan K, Corman H, Reichman N. Effects of maternal depression on family food insecurity. *Econom Hum Biol*. 2016;22:201–215.
 23. Center on Budget and Policy Priorities. *Policy Basics: Special Supplemental Nutrition Program for Women, Infants, and Children*; 2022. <https://www.cbpp.org/research/food-assistance/special-supplemental-nutrition-program-for-women-infants-and-children>.
 24. Children's Defense Fund. *The State of America's Children*; 2021. <https://www.childrensdefense.org/wp-content/uploads/2021/04/The-State-of-Americas-Children-2021.pdf>.
 25. US Department of Health and Human Services. Healthy People 2030. Children. <https://health.gov/healthypeople/objectives-and-data/browse-objectives/children>.

- Human immunodeficiency virus (HIV) (*Continued*)
- perinatal transmission of, prevention and reduction of, 631
 - postexposure prophylaxis for, 632, 632b
 - preexposure prophylaxis for, 631–632, 632b
 - screening, 74
 - sports and, 247t–250t, 256–257
 - testing schedule for, 630t
- Human papillomavirus vaccine, 279
- Human pneumovirus (metapneumovirus), 639
- Humidification, in respiratory management, 509
- Humidity, in physical activity and sports, 238–239
- Hyaline membrane disease, 399
- Hydration
- importance in respiratory management, 508
 - of skin, 711–712
- Hydrocele, 927–928, 927f
- Hydrocephalus, 900
- Hydrocodone, for acute pain management, 334
- Hydronephrosis, neonatal, 404
- Hydroxychloroquine, ocular side effects of, 464t
- Hydroxyurea, for sickle cell anemia, 786
- Hydroxyzine
- for allergic rhinitis, 683t
 - for atopic dermatitis, 688
- Hymenoptera, in children, 353–354
- Hyperadrenal states, 813–814
- Hyperbilirubinemia, 407–408, 408f
- Hypercholesterolemia, 830–831
- Hyper-IgE syndrome, clinical presentation of, 703t
- Hyperlipidemia, 830–831
- Hyperlordosis, 855
- Hyperoxia test, in cardiovascular system, 541
- Hyperparathyroidism, 818
- Hypersensitivity. *See* Delayed T-cell type reaction
- Hypertension, 542f, 558–560, 559f
- clinical findings of, 558
 - complications of, 560
 - diagnostic studies of, 558
 - history of, 558
 - management of, 559
 - patient and family education of, 560
 - physical activity and, 232
 - physical examination of, 558
 - sports and, 247t–250t, 254
- Hyperthermia, 359
- Hyperthyroidism, 816–817
- Hypertrophic cardiomyopathy, sports and, 247t–250t
- Hypnagogic hallucinations, 894
- Hypoglycemia, neonatal, 405, 406t
- Hypoparathyroidism, 817
- Hypopigmentation disorders, 760–762
- Hypoplastic left heart syndrome (HLHS), 552–553, 553f
- Hypoproliferative anemias, 776
- Hypospadias, 926
- Hypothalamic gonadotropin-releasing hormone (GnRH), 806
- Hypothalamic-pituitary-thyroid axis, 799, 801f
- Hypothalamus, 800t, 875t
- Hypothermia, 358–359
- Hypothyroidism, 814–816, 815b
- clinical findings in, 815–816
 - diagnostic studies in, 815–816
 - history in, 815
 - management of, 816, 816t
 - physical examination in, 815
- Hypotonic infant, 897–898
- Hypovolemia, 570
- Hypoxic-ischemic insults, 409, 410t
- I**
- IBD. *See* Inflammatory bowel disease
- IBS. *See* Irritable bowel syndrome
- Ibuprofen
- in fever management, 339, 339t
 - for headaches, 885t
 - for juvenile idiopathic arthritis, 692
- ICS. *See* Inhaled corticosteroid
- Idiopathic scoliosis, 853
- Idiopathic thrombocytopenic purpura. *See* Immune thrombocytopenia
- Idiopathic ulcers, 579–580
- IgA nephropathy, 921
- IgAV. *See* Immunoglobulin A vasculitis
- IgE-mediated reaction, 659
- IHPS. *See* Infantile hypertrophic pyloric stenosis
- Ill-child encounter, 32
- Illness, impact of, supporting families through, 372
- Image Gently, 3
- Imagination Library, 116
- Immune deficiency, pathophysiology and defense mechanisms of, 660
- Immune response, 265
- Immune system
- of infants, 103–104, 104f
 - innate, 660, 702–703
 - physiology of, 702–703
- Immune thrombocytopenia, 788–789
- Immune-complex reactions, 659
- Immunization, 265–282, 349
- adverse events following, 272
 - documentation of, 277
 - for infectious diseases, 614
 - practice guidance for, 266–267
 - for seizures, 892
- Immunoglobulin A vasculitis (IgAV), 700–701
- clinical findings of, 700
 - complications of, 700–701
 - diagnostic studies of, 700
 - differential diagnosis of, 700
 - history of, 700
 - management of, 700
 - patient and parent education in, 701
 - physical examination of, 700
 - prognosis of, 700–701
- Immunoglobulins, in children, 619t–621t
- Immunologic memory, 265
- Immunomodulator agents, for Crohn disease, 593
- Immunoserology, in infectious diseases, 614
- Immunosuppressed persons, invalid
- contraindications and precautions in, 270–271
- Immunosuppression, contraindications and precautions in, 269–270
- Imperforate anus, 401–402
- Imperforate hymen, 943, 943f
- Impetigo, 716–718, 716t, 717f
- Implant, contraceptive, 956–957
- Imuran. *See* Azathioprine
- Inactivated vaccines, 266, 277–280
- dengue, 279
 - diphtheria-tetanus-acellular pertussis, 271
 - for 6 weeks to 6 years, 277
 - for 7 years through adulthood, 277–278
 - Haemophilus influenzae*, 278
 - hepatitis A, 278
 - hepatitis B, 278
 - human papillomavirus, 279
 - influenza, 280
 - meningococcal, 279
 - pneumococcal, 278, 279b
 - polio, 278
- Inborn errors of metabolism, 832–834
- assessment of, 832–834
 - clinical findings in, 833–834
 - diagnostic studies for, 833–834
 - history of, 833
 - pathophysiology of, 832, 833f
 - physical examination of, 833
 - signs/symptoms suggesting, 832b
- Inclusion, in healthcare system, 27–30
- Inclusion conjunctivitis, 473
- Indoor air pollution, 21, 22t
- primary care educational strategies for, 23
- Infant jaundice, 97
- Infant mortality
- in healthcare system, 29
 - in the United States, 9
- Infantile acne, 742
- Infantile hemangiomas, 756
- Infantile hypertrophic pyloric stenosis (IHPS), 577
- Infantile polyarteritis. *See* Kawasaki disease
- Infants
- behavioral assessment of, 48
 - developmental issues in, 110–111
 - developmental management of, 103–119
 - cognitive, 106t–108t, 109
 - communication and language, 106t–108t, 109–110
 - gross and fine motor skills, 105–109, 106t–108t
 - health supervision, 111–118
 - overview of, 103–110
 - physical, 103, 105, 106t–108t
 - screening for, 113t, 118
 - social and emotional, 106t–108t, 109
 - of a diabetic mother, 405, 406t

Infants (*Continued*)

- elimination pattern in, 217t
 - environmental risk factors for, 13t–14t
 - HIV transmission to, 629
 - medication management in, 322
 - organ/system maturation of, 103–105
 - patterns of sexuality in, 72
 - periodic wellness visit for, 111–118, 114t–115t
 - physical growth of, 103, 105
 - from 1 to 3 months, 105
 - from 4 to 6 months, 105
 - from 6 to 8 months, 105
 - from 9 to 12 months, 105
 - pneumonia forms in, 525t
 - posttraumatic stress disorder symptoms in, 426t
 - red flags for, 114t–115t, 118
 - sexual behaviors, self-concept, and relationships of, 73t
 - urinary tract infections in, 911t, 912
- Infant-Toddler and Family Instrument (ITFI), for infants, 113t
- Infections
- central nervous system, 903–904
 - growth faltering and, 595t
 - modes of transmission in childcare settings, 615t
 - of newborn, 410–413
 - congenital rubella, 411
 - congenital varicella, 412–413
 - cytomegalovirus, 411
 - group B *Streptococcus*, 412
 - listeriosis, 412
 - toxoplasmosis, 410–411
 - preventing spread of, 614
 - traumatic herpetic, 623
- Infectious diarrhea, probiotics for, 568
- Infectious diseases, 610
- antibiotics for, 614
 - bacterial, 645–647
 - cat-scratch disease, 647–648
 - community-acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA), 645–647, 646f, 647t
 - Kingella kingae* infection, 648
 - meningococcal disease, 648–649
 - streptococcal disease, 649–655
 - tuberculosis, 651–655
 - in bioterrorism, 656
 - clinical findings, 610–614
 - general management strategies in, 614–615
 - helminthic zoonoses, 655–656
 - history of, 610–612
 - imaging techniques, 614
 - laboratory and imaging studies in, 613–614
 - parasitic-caused, 640–641
 - pathogenesis of, 610–614, 611t–612t
 - vaccines for, 614–615
 - viral, 615–656
 - coronaviruses, 639–640
 - enteroviruses, 615–617

Infectious diseases (*Continued*)

- erythema infectiosum, 634–635, 634f
 - Hantavirus pulmonary syndrome, 638–639
 - hepatoviruses, 617–622
 - herpes family of viruses, 622–626
 - human calicivirus infections (Norovirus and Sapovirus), 639
 - human immunodeficiency virus, 628–632
 - human pneumovirus (metapneumovirus), 639
 - influenza, 626–628
 - measles (rubeola), 632–633
 - Middle-Eastern respiratory syndrome, 640
 - mosquito-borne, 636–638
 - mumps, 633–634
 - parainfluenza, 635
 - potential emerging and reemerging, 640–641
 - rubella (German or 3-day measles), 635–636
 - tick-borne, 641–645
- Infectious mononucleosis, 624–625
- complications of, 624–625
 - diagnostic studies of, 624
 - differential diagnosis and management of, 624
 - patient and family education for, 624–625
 - sports and, 255
- Infective endocarditis, 560–561
- clinical findings of, 561
 - complications of, 561
 - diagnostic studies of, 561
 - differential diagnosis of, 561
 - history of, 561
 - management of, 561
 - patient and family education of, 561
 - physical examination of, 561
- Infestations, of skin, 734–739
- pediculosis, 734–737, 736t
 - scabies, 737–739, 738f
- Inflammatory bowel disease (IBD), 591–592
- Crohn disease, 592–593
 - ulcerative colitis, 593–594
- Inflammatory disorders, 659–708
- atopic disorders, 661–690
 - allergic rhinitis, 678–685
 - asthma, 662–678
 - atopic dermatitis, 685–690
 - pathophysiology and defense mechanisms of, 659–660
 - pathophysiology and defense mechanisms of, 659–660
 - pediatric vasculitis, 699–702
 - immunoglobulin A vasculitis, 700–701
 - Kawasaki disease, 701–702
 - primary immunodeficiency disorder, 702–704
 - clinical presentation of, 703t, 704
 - diagnostic studies of, 704
 - history of, 704
 - management of, 704
 - physical examination of, 704
 - warning signs of, 704b
- principles of, 659–661
- rheumatologic disorders, 690–699
- acute rheumatic fever, 697–699
 - juvenile fibromyalgia, 695–696, 695b
 - juvenile idiopathic arthritis, 690–693
 - myalgic encephalomyelitis/chronic fatigue syndrome, 696–697
 - pathophysiology and defense mechanisms of, 660, 661t
 - poststreptococcal reactive arthritis, 699
 - systemic lupus erythematosus, 693–695
- Inflammatory pain, 330b
- Influenza vaccine, 280
- Influenza viral infections, 626–628
- highly pathogenic avian, 628
 - typical, 626–628
 - clinical findings in, 626–628
 - diagnostic studies for, 628
 - differential diagnosis, management, and complications of, 628
- Inguinal hernia, 927f, 929
- Inhaled corticosteroid (ICS)
- for allergic rhinitis, 683, 684t
 - for asthma, 669, 674t–677t
- Inheritance, patterns of, 376–379
- Mendelian, 376–378
 - autosomal dominant in, 376, 377f, 378t
 - autosomal recessive in, 376–377, 377f
 - X-linked inheritance in, 377–378
 - non-Mendelian, 378–379
- Injuries, 345–364
- bites and stings, 352–357
 - animal and human bites, 352–353
 - Hymenoptera, 353–354
 - mosquitoes, fleas, and chiggers (red bugs or harvest mites), 354–355
 - snakebites, 356–357
 - spiders and scorpions, 355–356
 - control, 299, 300t
 - female athlete and, 260–261
 - from heat and cold, 357–359
 - frostbite, 357–358, 358t
 - hyperthermia, 359
 - hypothermia, 358–359
 - in skeletal system, 843
 - trauma, 345–352
 - abrasion, 345
 - burns, 349–352, 350t, 351b
 - contusion, 352
 - hematoma, 352
 - lacerations, 347–349
 - puncture wounds, 346–347, 347t
- Innate immune system, 660, 702–703
- Innocent murmurs, 540–541, 541b, 542t
- Inspection, of orthopedic system, 844
- Insulin
- dosing, 822
 - adjustment of, 822
 - therapy with, 820–822
 - usual sites for injection of, 821

- Insulin pump, 821
- Integrative therapies, 325–326
- Intellectual and physical developmental disabilities (I/P/DD), individuals with, sexuality in, 79–80, 80b
- Intellectual development, in early childhood, 130
- Intellectual disability and global developmental delay, 443–445
clinical findings and assessment of, 444
definition and diagnostic criteria for, 443–444, 443b
diagnosis, screening and specialty referral for, 444
follow-up and referral of, 445
management of, 444
- Intentional weight loss and weight gain, for athletes, 236–238
- Interdisciplinary team, in palliative care, 365–366, 367b
- Interferon γ release assays, for tuberculosis, 652
- Intergovernmental Panel on Climate Change (IPCC) Report, 8
- Internal reproductive organs, 938, 938f
- Internal rotation, 845–846, 848f
- Intertrigo, 745t
- Intestinal parasites, 606
clinical findings of, 603t–605t, 606
differential diagnosis of, 606
management of, 606, 607t
patient and family education in, 606
- Intestinal polyps, 590–591
- Intestines, gastrointestinal system and, function of, 566
- Intimate partner violence (IPV), 304
- In-toeing and out-toeing rotational problems, 866, 867f, 867t
- Intraarticular corticosteroids, for juvenile idiopathic arthritis, 692–693
- Intracranial pathology
physical abuse, 309
structural, red flags suggestive of, 884b
- Intramuscular injections, various ages for, needle lengths and injection sites for, 276
- Intraoral injury, physical abuse, 309
- Intrauterine compression deformations, 842–843
- Intrauterine devices, 952f, 957
- Intraventricular hemorrhage, 409
- Intussusception, 583–585
clinical findings of, 583–584
complications of, 585
diagnostic studies of, 583–584, 585f
differential diagnosis of, 584
history of, 583
management of, 584–585
physical examination of, 583
- Iodine, topical, 289, 296–297
- IPV. *See* Intimate partner violence
- Iron, 176, 177t–178t
- Iron chelation, for β -thalassemia major, 783
- Iron deficiency anemia, 776–782, 778t
clinical findings in, 778–779, 780t
diagnostic studies in, 778–779, 780b
differential diagnosis for, 779–780, 781b
lead poisoning and, 780–781
management of, 781
patient and family education for, 782
prevention of, 781–782
risk factors for, 780b
screening for, 778
- Iron supplementation, 781
- Irritable bowel syndrome (IBS), 587
clinical findings of, 587
differential diagnosis of, 587
management of, 587
probiotics for, 568
- Irritant contact dermatitis, 744, 745t
- Isolated proteinuria, 918
- Isoniazid, ocular side effects of, 464t
- Isotretinoin
for acne, 741–742
ocular side effects of, 464t
- ITFI. *See* Infant-Toddler and Family Instrument
- Ivermectin, topical
for pediculosis, 736
- J**
- Jaquet dermatitis, 744
- Jaundice
with hepatitis, 617
infant, 97
- JFM. *See* Juvenile fibromyalgia
- JIA. *See* Juvenile idiopathic arthritis
- Jock itch. *See* Tinea cruris
- Justice, in healthcare system, 27–30, 28f
- Juvenile arthritis (JA), limping and, 869t–870t
- Juvenile dermatomyositis, idiopathic myositis, sports and, 247t–250t
- Juvenile fibromyalgia (JFM), 695–696, 695b
- Juvenile idiopathic arthritis (JIA), 690–693
clinical findings of, 691–692
complications of, 693
diagnostic studies of, 691–692
differential diagnosis of, 692
history of, 691
management of, 692–693
patient and parent education in, 693
physical examination of, 691
prevention of, 693
prognosis of, 693
subtypes and clinical joint characteristics of, 690b
- Juvenile polyps, 590
- Juvenile rheumatoid arthritis, sports and, 247t–250t
- K**
- Karyotyping, for congenital and inherited disorders, 384–385
- Kawasaki disease (KD), 701–702
- Keloid, 712b
- Keratitis, 478–479
- Keratorefractive (laser-assisted in situ keratomileusis [LASIK]) surgery, 462
- Keratosis pilaris, 756
atopic dermatitis and, 687
clinical findings of, 756
differential diagnosis of, 756
patient and family education for, 756
- Ketogenic diet, 891
- Ketone utilization disorders, 835t
- Kidneys
absence of one, sports and, 247t–250t
anatomy and physiology of, 908
hormones and, 800t
- Kiesselbach plexus, 522
- Kingella kingae* infection, 648
- Klinefelter syndrome, clinical findings and primary care issues of, 386t–390t
- Klisc test, 845, 847f
- Knee injuries, 863, 864t–865t
- Knock-knees, 861
- Koebner phenomenon, 753
- Kyphosis, 853, 854t, 855
- L**
- Labeling, pharmaceutical, 320
- Labial adhesions, 943, 943f
- Labial appearance, concerns about, 945
- Laboratory tests, for gastrointestinal disorders, 567
- Lacerations, 347–349
in physical activity, 237t–238t
- Lactase nonpersistence, 588
- Lactation, induced, 192
- Lactation consultants, in human milk, 192
- Lactobacillus*, 568
- Lactose intolerance, 588
complications and prognosis of, 590
management of, 590
specific tests for, 589
- Language delays, in early childhood, 137
- Language development
in early childhood, 125t, 130, 134t, 135
in infants, 106t–108t, 109–117
in middle childhood, 141–142, 142t, 148t–150t
- Laryngotracheitis croup, 515, 516t
- Laryngotracheobronchitis (LTB), 515–517
clinical findings of, 515
complications of, 517
diagnostic studies of, 515
differential diagnosis of, 515
differentiating from similar diseases, 516t
history of, 515
indications for hospitalization, 517
management of, 515–517, 516t
physical examination of, 515
- Larynx, anatomy and physiology of, 503
- Lateral tibial torsion (LTT), 862
- Latex, allergic reactions and, 269
- Latex dermatitis, 743
- LCPD. *See* Legg-Calvé-Perthes disease
- Lead, 360, 362t
poisoning, iron deficiency and, 780–781

- Learning challenges
 in childhood development, 41, 41t
 in middle childhood, 143, 144t–146t
- Learning theories, 87–88
- Left-to-right shunting, 548–551, 548f
- Leg aches, of childhood, 867–868
- Legg-Calvé-Perthes disease (LCPD), 857–858, 858f
 clinical findings of, 857
 complications of, 858
 differential diagnosis of, 857
 limping and, 869t–870t
 management of, 858
- Leg-length inequality, limping and, 869t–870t
- Length, of infants, 103
- Lentiginos, 756, 757b, 759f
- LES. *See* Lower esophageal sphincter
- Lesbian, gay, bisexual, transgendered, and questioning youth (LGBTQ), 80–81
 terms, glossary of, 81b
- Let-down reflex, 193
- Leukemias, 793–794
- Leukocyte esterase, in urine, 909
- Leukocytes, 769–770, 771t–772t
 in urine, 909
- Leukotriene modifiers
 for allergic rhinitis, 683–684
 for asthma, 676t–677t
- Lexicon, in early childhood, 126
- LGBTQ. *See* Lesbian, gay, bisexual, transgendered, and questioning youth
- Lichen sclerosis, 942–943, 943f
- Lichen striatus, 755–756
- Lichenification, 712b
- Licorice, ocular side effects of, 464t
- Life course perspective, in adverse childhood experiences, 3
- Lifestyle
 changes, for diabetes mellitus, 826
 and hypertension prevention, 560
- Limb, formation of, 841
- Limping, 845, 868–870
 clinical findings of, 868
 differential diagnosis of, 869t–870t, 870
 management of, 870
 types of, 868t
- Lipids, in human milk, 192
- Lip-licker dermatitis, 743
- Listeria monocytogenes*, 598t–600t
- Listeriosis, 412
- “Little League elbow”, 871t
- “Little League shoulder”, 871t
- Live attenuated vaccines, 266, 280–281
 injectable, antibody-containing products
 and, 267–268
 measles, mumps and rubella, 280
 nonsimultaneous administration of, 267
 oral and intranasal, antibody-containing
 products and, 268
 rotavirus, 280
 varicella, 281
- Liver, enlarged, sports and, 247t–250t
- Lobar pneumonia, 521–522
- Long bones, fractures of, 843–844
- Long QT syndrome, sports and, 247t–250t
- Long-acting β_2 -agonists, inhaled, for asthma,
 676t–677t
- Long-chain fatty acid oxidation defects, 835t
- Lordosis, 854t
- Lorenz, Konrad, 88
- Loss, 61–62
- Lower airway and parenchymal
 conditions
 acute conditions, 523–527
 chronic conditions, 528–531
- Lower airway obstruction, 505
- Lower esophageal sphincter (LES), 566
- Lower gastrointestinal tract disorders,
 581–606
 anal fissures, 591
 appendicitis, 582–583
 diarrhea, 597–606
 foreign body ingestion, 581–582
 functional abdominal pain-not otherwise
 specified, 585–587
 growth faltering, 594–597, 594b
 Hirschsprung disease (congenital
 aganglionic megacolon), 585
 inflammatory bowel disease, 591–592
 intestinal and rectal polyps, 590–591
 intestinal parasites, 606
 intussusception, 583–585
 irritable bowel syndrome, 587
 malabsorption syndromes, 587–590
- Lower leg length, BM–APP, BM–APP
- LTB. *See* Laryngotracheobronchitis
- LTT. *See* Lateral tibial torsion
- Lubrication, of skin, 711–712
- Lumbar lordosis, 855
- Lumbar puncture, 880
- Lungs, in newborn assessment, 93
- Luteinizing hormone (LH), 806
- Lyme disease, 641–644, 642f
 clinical findings in, 641–643
 diagnostic studies of, 643
 differential diagnosis, management, and
 complications of, 643–644
 patient and family education in, 644
- Lymph node disease, 654
- Lymphadenopathy, 636
- Lymphocytes, 770, 771t
- Lymphocytosis, 792
- Lymphopenia, 629
- Lysosomal storage disorders, 835t, 836
- M**
- Macrocephaly, 901
- Macrocytic anemias, 784
- Macronutrients, for athletes, 242–244
- Macule, 712b
- Magnesium, 175–176, 177t
- Magnesium sulfate, intravenous, for acute
 asthma exacerbations, 674–675
- Magnetic resonance imaging (MRI)
 of cardiovascular system, 541
 for gastrointestinal disorders, 568
 for musculoskeletal system, 846–847
 of nervous system, 880
- Mahler, Margaret, 85
- Major anomaly, 381, 384t
- Malabsorption syndromes, 587–590
 clinical findings of, 588–589
 complications and prognosis of, 590
 differential diagnosis of, 589
 history of, 588–589
 management of, 589–590
- Malaria, 640–641
- Malassezia ovalis*, 746
- Malformations, 381
- Malignancy and autoimmune disorders,
 growth faltering and, 595t
- Malignant neoplasm, sports and, 247t–250t
- Malignant ventricular arrhythmias, sports and,
 247t–250t
- Malocclusion, 293
- Malrotation with volvulus, 400–401
- Manhattan Project, 28
- Mantoux tuberculin skin test, 652
- Maple syrup urine disease, 835t
- Marfan syndrome
 clinical findings and primary care issues of,
 386t–390t, 392f
 sports and, 247t–250t
- Mastalgia, 951
- Mastitis, 202, 202f
- Maternal mortality rate (MMR), 6
- Maturation, in pediatric assessment, 31
- Maturation anemias, 776
- Mature milk, 192
- Maturity-onset diabetes of the young
 (MODY), 827
- MDI. *See* Metered dose inhaler
- Measles, 632–633
 clinical findings in, 633
 complications of, 633
 diagnostic studies for, 633
 differential diagnosis and management of, 633
 exposed individuals to, care of, 633
 German or 3-day, 635–636
- Measles, mumps and rubella vaccines, 280
- Mebendazole (Emverm), for intestinal
 parasites, 607t
- ME/CFS. *See* Myalgic encephalomyelitis/
 chronic fatigue syndrome
- Meconium aspiration syndrome, 399–400
- Meconium ileus, 403
- Medial collateral ligament (MCL), sprain of,
 864t–865t
- Medial tibial stress syndrome, in physical
 activity, 237t–238t
- Medial tibial torsion (MTT), 862
- Medical child abuse (MCA), 314, 314b–315b
- Medical home, in pediatric primary care, 1
- Medical neighborhood, in pediatric primary
 care, 1

- Medical nutrition therapy, for diabetes mellitus, 822
- Medication adherence, 322–324, 323t
- Medications
- for acute otitis media, 496t–497t
 - in children with cerebral palsy, 897
 - in children with special health care needs, 296, 296b
 - for dermatologic disorders, 713–714, 713b
 - for gastroesophageal reflux disease, 579t
 - for gastrointestinal disorders, 568
 - for neurologic disorders, 881
 - on nutritional status, 186
 - ophthalmic, 462–463
 - prescribing, 320–328
 - National Safety Goals regarding, 320
 - in pediatrics, 321
 - for respiratory system, 509–510
- Medium, in epidemiologic model, 15
- Medium-chain fatty acid oxidation defects, 835t
- Medulla, 875t
- Melanocytic nevi, 756
- Melatonin, 206
 - for atopic dermatitis, 688
- Membranoproliferative GN, 921
- Menactra. *See* MenACWY-D vaccine
- MenACWY-D (Menactra) vaccine, 267
- Menarche, isolated, 807
- Mendelian inheritance patterns, 376–378
 - autosomal dominant in, 376, 377f, 378t
 - autosomal recessive in, 376–377, 377f
 - X-linked inheritance in, 377–378
- Meningitis, tuberculous, 654–655
- Meningococcal disease, 648–649
 - clinical findings in, 648–649
 - diagnostic studies in, 649
 - differential diagnosis of, 649
 - management, control measures, and complications of, 649
- Meningococcal meningitis, 649
- Meningococcal vaccines, 279
- Meningococcemia, 649, 649f
- Meningoencephalitis, acute herpetic, 623
- Meniscal tear, 864t–865t
- Menstrual bleeding
 - heavy, 948
 - physiology of, 939, 939b, 940f
- Menstrual cycle, 938–939
 - anovulatory, 939, 940b
 - coagulation pathway and, 939, 940b
 - ovulatory, 939, 940b
- Mental health
 - assessment of, 47–49
 - approaches to, 48
 - history in, 48–49
 - physical examination and diagnostic studies for, 49
 - social-emotional development and behavioral screening for, 49, 50t
 - underlying principles of, 47–48
 - foundations of, 38–47
- Mental health (*Continued*)
 - emotional well-being as, 38–39, 39t
 - family and community influence on, 45–47
 - protective, promotive, and risk factors as, 41–43, 42t
 - relationships and attachment in, 43–44
 - science of early childhood development and, 39–41, 39f, 41t, 42f
 - social-emotional and spiritual development as, 44–45, 45f
 - management strategies, 49–58
 - sleep and, 213–214
- Mental health disorders, 419–455
 - aggression and disruptive behavior disorders, 445–446
 - anxieties, 421
 - attention-deficit/hyperactivity disorder, 431–441
 - autism spectrum disorder, 447–451
 - bipolar disorder, 430–431
 - conduct disorder, 446
 - depression, 427
 - disruptive mood dysregulation disorder, 447
 - eating disorders, 451–452
 - generalized anxiety disorder, 422, 423f
 - intellectual disability and global developmental delay, 443–445
 - mood disorders, 427–430
 - obsessive-compulsive disorder, 422–425, 425b
 - oppositional defiant disorder, 446–447
 - posttraumatic stress disorder, 426–427, 426t
 - separation anxiety disorder, 421–422
 - specific learning disorders, 441–443
 - substance abuse disorder, 453–454
 - tic disorders, 425–426
- Mental health disparities, in healthcare system, 29
- Mentzer Index, 780b
- Mercury, 363b
- Mercury levels, from amalgams, 289–290
- Mesenchymal response, 709–710
- Metabolic conditions, neonatal, 405
- Metabolic crisis, 834
- Metabolic disorders, 799–840
 - amino acid, 836
 - in children, 834–836, 835t
 - classification of, 815b
 - dyslipidemias, 830–831, 831t
 - emergencies, 834
 - of fatty acid oxidation, 836
 - hypercholesterolemia, 830–831
 - hyperlipidemia, 830–831
 - inherited, 803b, 832
 - lysosomal storage disorders, 836
 - obesity, 828–830
 - phenylketonuria, 836
 - urea cycle, 836
- Metabolic pathways, 833f
- Metabolic syndrome, 831–832
 - physical activity and, 232
- Metabolic system, growth faltering and, 595t
- Metabolism, to toxic agents, 14
- Metapneumovirus. *See* Human pneumovirus
- Metatarsus adductus, 865–866, 865f
- Metered dose inhaler (MDI), for asthma, 669, 677t–678t, 682b
- Metformin, for type 2 diabetes, 826
- Methadone, neonatal exposure to, 414–416
- Methicillin-resistant *Staphylococcus aureus*, community-acquired, 645–647, 646f, 647t
- Methotrexate, for systemic lupus erythematosus, 695
- Methylenetetrahydrofolate reductase (MTHFR), 899
- Methylmalonic acidemia, 835t
- Microcephaly, 901, 901b
- Microcytic anemia, 776–782
- Microscopic urine examination, 909
- Midbrain, 875t
- Mid-childhood acne, 742
- Middle childhood
 - common developmental concerns in, 142–143
 - learning challenges, 143
 - school adjustment, 142–143, 144t–146t
 - school refusal, 143
 - developmental management of, 139–152
 - cognitive development, 141
 - communication and language development, 141–142, 142t
 - emotional development, 141
 - gross and fine motor development, 139–140
 - physical growth and development, 139, 140t
 - social development, 140–141
 - developmental red flags for, 151, 152t
 - developmental sleep considerations in, 208t, 209
 - environmental risk factors for, 13t–14t
 - health promotion topics in, 143–146
 - nutrition, 144, 147t
 - oral health, 144, 147t
 - safety, 146, 147t
 - sleep, 144–146, 147t
 - health supervision visits, 147–150, 148t–150t, 150b
 - anticipatory guidance, 148t–150t, 150
 - history, 147, 148t–150t, 150b
 - physical examination, 147–150
 - screening, 150, 151t
 - patterns of sexuality in, 72–74, 74b
 - sexual behaviors, self-concept, and relationships of, 73t
- Middle-Eastern respiratory syndrome, 640
- Migraine headache, types of, 882b
- MII. *See* Multichannel intraluminal impedance
- Mild illness, invalid contraindications and precautions in, 270
- Milia, 712b
 - in newborn, 99t

- Miliaria, 745t
 Military deployment, 66
 Milk ejection reflex, 193
 Milk production, stages of, 192
 Mindfulness, 56
 Mindset, growth, 46, 46t
 Mineral supplements, 181
 in adolescent, 183
 in early childhood, 181
 in middle childhood, 181–183
 Minerals, 177t
 for athletes, 243t
 in human milk, 193
 supplements, 173–176
 Minocycline hydrochloride, ocular side effects of, 464t
 Minor anomaly, 381, 384t
 miRNA, 379–380
 Mitochondrial disorders, 379, 835t
 Mitochondrial inheritance, 378
 Mitral valve prolapse, sports and, 247t–250t
 Mittelschmerz, 950
 Mixed dentition, 284
 MMR. *See* Maternal mortality rate
 Mobility, in children with cerebral palsy, 897
 Modulation, of pain, 329
 MODY. *See* Maturity-onset diabetes of the young
 Moisturizers, for skin, 711–712
 Molds, as air pollutant, 22t
 Molecular testing, for congenital and inherited disorders, 384–385
 Molluscum contagiosum, 732–733, 733f
 Monoamines, 878t
 Monocytes, 770, 771t
 Mood disorders, 427–430
 bipolar, 430–431
 depression, 427
 Moral development, 45
 in early childhood, 123
 Morbidity, in type 1 diabetes, 823
 Morgan line
 allergic rhinitis and, 682f
 atopic dermatitis and, 687
 Morphine, for acute pain management, 334
 Mortality
 global pediatric, 7
 in type 1 diabetes, 823
 Mosaicism, 379
 Mosquitoes, bites of, 354–355
 Mother-to-child transmission (MTCT), of HIV, 629
 Motivational interviewing, 57, 57t–58t
 Motor skills development, 93
 in adolescents, 156–157
 in early childhood, 120, 122t, 130
 in infants, 105–109, 106t–108t
 in middle childhood, 139–140, 148t–150t
 Motor vehicle-related injuries, 301–302, 301f
 Mouth
 bacterial diseases of, 287–290
 viral disease of, 290–291
 Movement, in children with cerebral palsy, 897
 MRI. *See* Magnetic resonance imaging
 mRNA vaccines, 281
 MTT. *See* Medial tibial torsion
 Mucocele, 293, 293f
 Mucocutaneous lymph node syndrome. *See* Kawasaki disease
 Mucus, bulb syringe and, 509
 Multichannel intraluminal impedance (MII), for gastroesophageal reflux disease, 575
 Multifactorial disorders, 379
 Multiple sclerosis, 906, 906b
 Multisystem inflammatory syndrome in children (MIS-C), 562, 640
 Mumps, 633–634
 clinical findings in, 633–634
 diagnostic studies in, 634
 differential diagnosis, management, and complications of, 634
 Munchausen syndrome by proxy, 314
 Muscle soreness, in physical activity, 237t–238t
 Muscles, diseases of, 871–872
 Muscular function, in children with special health care needs, 296
 Musculoskeletal disorders, 841–873
 annular ligament displacement as, 849–850, 850f
 back pain as, 852–853
 brachial plexus injuries as, 850–851, 850t
 clavicle fracture as, 851–852
 costochondritis as, 852
 developmental dysplasia as, 855–857
 developmental dysplasia of the hip, 855–857
 femoral anteversion as, 860
 ganglions of hands as, 872
 genu valgum as, 861–862, 861f
 genu varum as, 860–861, 861f
 in-toeing and out-toeing rotational problems as, 866, 867f, 867t
 knee injuries, 863
 kyphosis as, 854t, 855
 leg aches of childhood as, 867–868
 Legg-Calvé-Perthes disease as, 857–858, 858f
 limps as, 868–870, 868t–870t
 lordosis as, 854t
 lumbar lordosis as, 855
 metatarsus adductus as, 865–866, 865f
 muscle diseases, 871–872
 Osgood-Schlatter disease as, 862–863
 overriding toes as, 866
 overuse syndromes as, 870–871, 871t
 pes planus as, 863–865
 popliteal cysts as, 872
 scoliosis as, 853–855, 854t
 slipped capital femoral epiphysis as, 858–860, 859f
 in sports, 247t–250t, 258–260
 burners, 259
 concussions, 247t–250t, 259–260, 259b, 260t
 Musculoskeletal disorders (*Continued*)
 head injury, 259–260
 neck injury, 259
 stingers, 259
 sternochondritis as, 852
 talipes equinovarus as, 866
 tibial torsion as, 862
 toe walking as, 867
 Musculoskeletal system
 anatomy and physiology of, 841–842, 842f
 assessment of, 844–847
 back examination for, 846
 defense mechanisms of, 843–844
 diagnostic studies for, 846–847
 effect of cystic fibrosis on, 530
 gait examination for, 845
 hip examinations for, 845–846
 inspection and palpation of, 844
 management strategies for, 847–849
 orthopedic conditions specific to pediatrics, 849–872
 pathophysiology of, 842–843
 posture and, 845
 range-of-motion examination for, 844–845
 Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), 696–697
 Myasthenia gravis (MG), 905–906
 Mycoplasma pneumoniae, 525t
 Myelomeningocele, 409–410
 Myocarditis, 561–562, 616
 Myoglobinuria, 923
 Myopathies, sports and, 247t–250t
 MyPlate, nutrition education and, 180, 180f
 N
 Nail signs, 754
 Nails, anatomy, 709
 Naproxen sodium
 in fever management, 339
 for headaches, 885t
 Narakas classification, of brachial plexus injuries, 850t
 Nasacort AQ. *See* Triamcinolone
 Nasal foreign body, 520–521
 Nasolacrimal duct conditions, 477–478, 477f
 Nasopharyngitis, 513
 Nasopharynx, anatomy and physiology of, 503
 National Patient Safety Goals (NPSG), 320
 National Safety Goals, regarding prescribing medications, 320
 National Sleep Foundation (NSF), 210
 Nature-deficit disorder, 4
 Nebulizer solution, for asthma, 677t–678t
 Neck injury
 in physical activity, 237t–238t
 in sports, 237t–238t, 259
 Necrotizing enterocolitis, 402–403
 Necrotizing fasciitis, 719, 719f
 Necrotizing periodontal disease, 290
 Neonatal abstinence syndrome, 414, 415f
 cocaine (crack) exposure, 414
 heroin and methadone exposure, 414–416

- Neonatal acne, 742, 742f
- Neonatal brachial plexus palsy, 850
- Neonatal circulation, 536
- Neonatal Drug-Withdrawal Scoring System, 414, 416t
- Neonatal intensive care units (NICUs), 29
- Neonatal opioid withdrawal syndrome, 414
- Neonatal respiratory distress syndrome (NRDS), 399, 399t
- Neonates
- circulation, 536
 - conditions in, 396–416
 - amniotic band/constriction syndrome, 396
 - branchial cleft and thyroglossal cysts and sinuses, 396
 - central nervous system, 408–410
 - cleft lip and palate, 398
 - congenital cataracts, glaucoma, and retinopathy of prematurity, 398
 - endocrine, 405
 - gastrointestinal and abdominal, 400–403
 - hematologic, 405–408
 - infections, 410–413
 - meconium aspiration syndrome, 399–400
 - metabolic, 405
 - neonatal abstinence syndrome, 414, 415f
 - orthopedic, 408
 - renal, 403–405
 - sexually transmitted infections, 413–414
 - transient tachypnea of the newborn, 398–399
 - elimination pattern in, 217t
 - urinary tract infections in, 911t
- Neoplasm, limping and, 869t–870t
- Nephritis, 921–923, 922f
- Nephrolithiasis, 924–925
- Nephrotic syndrome, 920–921
- clinical findings of, 920
 - diagnostic studies for, 920
 - differential diagnosis of, 920
 - management of, 920–921
 - patient and family education for, 921
 - physical examination for, 920
 - prevention of, 921
 - prognosis of, 921
- Nervous system
- anatomy of, 874, 875f–876f, 875t
 - assessment of, 876–881
 - autonomic nervous system, 880
 - behavior, 879
 - coordination, 880
 - cranial nerve functions, 879, 879t
 - cranium examination, 880
 - developmental history, 877–879
 - diagnostic studies, 880–881
 - family history, 877
 - functional health, 877–879
 - history of present illness, 877
 - medical history, 877
 - meningeal signs, 880
 - mental status, 879
 - motor examination, 879–880
- Nervous system (*Continued*)
- neurologic examination, 879–880
 - physical examination, 879
 - reflexes, 880
 - sensory examination, 880
 - functions of, 875t
 - management strategies, 881
 - educational needs, 881
 - medications, 881
 - referrals for other key assessments, 881
 - pathophysiology and defense mechanisms of, 874–876
 - physiology of, 874
- Neural tube defects (NTDs), 379, 898–899
- Neurapraxia, sports and, 259
- Neuroblastoma, 404
- Neurodegenerative disorders, 906–907
- Neurodevelopmental disorders, 419
- sleep and, 213–214
- Neurodiversity, 420
- Neurofibromatosis type 1 (NF), 903
- clinical findings and primary care issues of, 386t–390t
- Neurologic disorders, 874–907
- disorders of head size or shape, 900–903
 - craniosynostosis, 901–903, 902f
 - macrocephaly, 901
 - microcephaly, 901, 901b
 - disorders of muscle tone, 894–898
 - cerebral palsy, 894–897, 895t, 895b–896b
 - hypotonic infant, 897–898
 - epileptic paroxysmal events, 889–893
 - epilepsy, 889–892, 889f–890f, 891t
 - febrile seizures, 892–893
 - sleep-related epilepsy, 892
 - headaches, 881–907, 882b–884b
 - infectious and immune-mediated, 903–906
 - Bell's palsy, 904
 - central nervous system infections, 903–904
 - Guillain-Barré syndrome, 905
 - myasthenia gravis, 905–906
 - Reye syndrome, 904–905
 - inherited, 903
 - neurodegenerative disorders, 906–907
 - multiple sclerosis, 906, 906b
 - Rett syndrome, 906–907
 - neuromuscular disorders
 - Chiari malformation, 900
 - congenital malformations, 898
 - Duchenne muscular dystrophy, 898
 - hydrocephalus, 900
 - neural tube defects, 898–899
 - spinal muscular atrophy, 898
 - tethered cord, 899–900, 900f
 - nonepileptic paroxysmal events, 893–894
 - benign paroxysmal vertigo, 893–894
 - narcolepsy, 894
 - psychogenic nonepileptic seizure, 893
 - sports and, 247t–250t
- Neurologic system, growth faltering and, 595t
- Neuromuscular disease, limping and, 869t–870t
- Neuromuscular scoliosis, 853
- Neuropathic pain, 330b
- Neuropeptide Y (NPY), 878t
- Neuropeptides, 878t
- Neurotransmitters, 874, 878t
- Neutropenia, 792
- Neutrophils, 770, 771t
- Nevi, pigmented, 756–759
- Nevus sebaceous, in newborn, 99t
- Nevus spilus, 758–759
- Newborn
- conjunctivitis in, 471–473
 - developmental management of, 91–102
 - common issues in, 93–98
 - discharge and follow-up for, 98, 100b
 - health supervision for, 98–100
 - intrauterine to extrauterine, transition, 91, 92f
 - newborn assessment in, 91–93
 - overview of, 93
 - transition to parenthood in, 91
 - developmental sleep considerations in, 208, 208t
 - environmental risk factors for, 13t–14t
- Newborn screening, for congenital and inherited disorders, 383–384
- Next-generation sequencing, for congenital and inherited disorders, 384–385
- NF1. *See* Neurofibromatosis type 1
- Nickel dermatitis, 743
- Nikolsky sign, 718
- Nipple discharge, 951
- Nipple preference, 202–203
- Nitazoxanide (Alinia), for intestinal parasites, 607t
- Nitric oxide, 878t
- Nitrites, in urine, 909
- Nitrofurantoin, for uncomplicated cystitis, 912
- Nits, 735, 736t
- Nociception, 329, 330f
- Nociceptive pain, 330b
- Nodule, 712b
- Nodulocystic acne, 740
- Noise, and hearing loss, 491–492
- Nonaccidental trauma, 843
- Nonanaphylactic allergy, invalid
 - contraindications and precautions in, 270
- Nonbinary adolescents, gynecologic considerations in, 953–954, 953t
- Nongonococcal conjunctivitis, 472
- Nongroup A or B streptococci, 651
- Non-Hodgkin lymphoma, 794–795
- Non-Mendelian inheritance patterns, 378–379
- Nonnutritive sucking, 116
- Nonpolio enteroviruses, 615–617, 616f
- Non-rapid eye movement (REM), 207
- Nonsedating antihistamines, for allergic rhinitis, 683t
- Nonsexual genital ulcers (NSGUs), 945f

- Nonsteroidal antiinflammatory drugs (NSAIDs)
 in acute pain management, 334
 for juvenile idiopathic arthritis, 692
 for systemic lupus erythematosus, 694–695
- Nonsuicidal self-injurious (NSSI) behaviors, 162–163
- Non-transfusion-dependent β -thalassemia (NTDT), 783
- Norepinephrine, 878t
- Normal microbiota, 610, 611t–612t
- Normocytic anemias, 784
- Norovirus, 598t–600t, 639
- Nostrils, anatomy and physiology of, 503
- NPSG. *See* Neonatal Patient Safety Goals
- NRDS. *See* Neonatal respiratory distress syndrome
- NSAIDs. *See* Nonsteroidal antiinflammatory drugs
- NSGUs. *See* Nonsexual genital ulcers
- NSSI. *See* Nonsuicidal self-injurious behaviors
- NTDs. *See* Neural tube defects
- Nursemaid's elbow, 849
- Nutrition, 171–189
 age-specific considerations of, 180–183
 in adolescent, 183
 early childhood, 181
 infants, 180–181
 in middle childhood, 181–183
 altered patterns of, 183–186
 in athletes, 242–245, 243t
 in children with cerebral palsy, 896
 in early childhood, 133–134
 focusing on weight, 186–188, 188b
 public perceptions and pressure surrounding weight, 186–187
 weight concerns in childhood, 187–188
 weight-neutral care, 187
 growth faltering and, 595t
 in infants, 113–117
 in middle childhood, 144, 147t
 optimal, management of, 177–183
 education, 180
 healthy eating habits, 178–180
 pediatric dietary guidelines, 171
 requirements and dietary reference intakes, 171–176, 171b
 carbohydrates, 173
 chloride, 172
 electrolytes, 172
 energy, 172
 fats, 173
 macronutrients, 172–173
 micronutrients, 173
 minerals and elements, 173–176
 potassium, 172
 protein, 172–173
 sodium, 172
 vitamins, 173
 water, 172
 status, assessment of, 176
 type 1 diabetes and, 822
 type 2 diabetes and, 826
- Nutritional supplements, 243–244
- Nystagmus, 467–468
- O**
- OAE. *See* Otoacoustic emission
- Obesity, 828–830
 bariatric surgery for, 829–830
 childhood, 9
 evaluation of, 828–829
 management of, 829, 829t
 physical activity and, 232
 sports and, 247t–250t
- Obsessive-compulsive disorder (OCD), 422–425, 425b
 clinical findings of, 423
 differential diagnosis of, 423–425
 management of, 425
- Obstetric brachial plexus palsy, 850
- Obstructive cardiac lesions, 553–555
 aortic stenosis and insufficiency, 553–554, 553f
 coarctation of aorta, 554–555, 555f
 pulmonic stenosis, 554
- Obstructive processes, in respiratory system, 505
- Obstructive sleep apnea, 213
- Occipital frontal (head) circumference, of infants, 103
- Occipital lobe, 875t
- Occlusion, 461
- Occlusive dressings, 713
- Occult bacteremia, 649
- Occult trauma, limping and, 869t–870t
- Occupational therapy, for orthopedic injury, 849
- OCD. *See* Obsessive-compulsive disorder
- Ocular toxocariasis, 656
- Office of Environmental Justice (OEJ), 20
- Off-label prescribing, 321–322
- OIT. *See* Oral immunotherapy
- Omphalocele, 402
- Onychomycosis, 722t, 728, 728f
- Ophthalmia neonatorum, 471–473
- Oppositional defiant disorder, 446–447
- Option talk, 35–36
- Oral antibiotics, for acne, 741
- Oral antihistamines, for allergic rhinitis, 682–683, 683t
- Oral candidiasis, 203
- Oral contraceptives, ocular side effects of, 464t
- Oral enteric peppermint oil capsules, for diarrhea, 602
- Oral examination, 285–286
- Oral health, in middle childhood, 144, 147t
- Oral Health Risk Assessment, for infants, 113t
- Oral immunotherapy (OIT), for allergic rhinitis, 684–685
- Oral mucositis, examination of, 285
- Oral steroids, for systemic lupus erythematosus, 695
- Orbit
 fractures of, 482
 lacerations of, 481
- Orchitis, 616
- Organ transplant recipients, sports and, 247t–250t
- Organs
 paired of, absence of, sports and, 258
 physical growth and development of, 93
- Orthopedic conditions, neonatal, 408
- Orthostatic proteinuria, 918
- Ortolani maneuver, 845, 847f
- Osgood-Schlatter disease, 862–863, 871t
- Osteochondritis dissecans, 864t–865t
- Osteogenesis imperfecta, 842
- Osteomyelitis, in puncture wounds, 346
- Osteopenia, in children with cerebral palsy, 897
- Otitis externa (OE), 491f, 493–494
 clinical findings of, 493–494
 complications of, 494
 diagnostic studies of, 493
 differential diagnosis of, 493–494
 history of, 493
 management of, 493
 physical examination of, 493
 prevention of, 494
- Otitis media
 acute, 494–501, 495f
 antibiotics for, 494t
 diagnostic studies of, 496
 management of, 496, 496t
 medications for, 496t
 risk factors for, 495b
 types of, 495t
 with effusion, 498–499, 498f–499f, 499b
- Otoacoustic emission (OAE), 488t
- Outdoor air pollution, 21
 primary care educational strategies for, 23
- Ovarian cysts, 950–951
- Ovarian insufficiency, 947
- Ovary, 800t
 absence of one, sports and, 247t–250t
- Overuse injuries, 843
 of childhood and adolescence, 870–871, 871t
 in sports, 258–260
- Ovulatory dysfunction, 947
- Ovulatory menstrual cycle, 939, 940b
- Oxygen, in respiratory management, 508–509
- Oxygen saturation, 539
- Oxyhemoglobin saturation percentage (SpO_2), 508
- P**
- Pain
 acute, 330b
 in children with cerebral palsy, 897
 inflammatory, 330b
 mechanisms of, 330b
 mixed, 330b
 neuropathic, 330b
 nociceptive, 330b
 pediatric. *See* Pediatric pain
 perception of, 329
 persistent, 330b
 procedural (incidental), 330b

- Pain (*Continued*)
 psychogenic, 330b
 recurrent, 330b
 somatic, 330b
 types of, 330b
 visceral, 330b
- Palliative care, pediatric, 365–375
 after death of child, 373
 barriers to, 373
 benefit from, 367t
 care coordination for, 372–373
 care delivery for, 372–373
 communication for, 369f
 components of, 366f
 epidemiology of, 366–367
 funding/insurance coverage for, 372–373
 interdisciplinary team in, 365–366, 367b
 levels of, 365
 principles of, 366b
 referral for, 368b
- Palpation
 in cardiovascular system assessment, 539, 539f
 of orthopedic system, 844
- Pancreas, 800t
- Pancytopenia, 791
- Pantoprazole (Protonix), for gastroesophageal reflux disease, 579t
- Papule, 712b
- Papulopustular acne, 740
- Papulosquamous eruptions, of skin, 752–756
 keratosis pilaris, 756
 lichen striatus, 755–756
 pityriasis rosea, 752–753, 752f
 psoriasis, 753–755, 754f
- PAQLQ. *See* Pediatric Asthma Quality of Life Questionnaire
- Parainfluenza virus, 635
- Paralytic disease, 616
- Paraphimosis, 932
- Parasites, modes of transmission in childcare settings, 615t
- Parasitic-caused disease, 640–641
- Parasomnias, 211–213
- Parasympathetic system, functions of, 877b
- Parathyroid disorders, 817–818
 anatomy and physiology, 817
 hyperparathyroidism, 818
 hypoparathyroidism, 817
 pseudohypoparathyroidism, 817
 transient hypoparathyroidism, 817–818
- Parathyroid gland, 800t
- Parenchyma, 503
- Parent
 adolescent, 66–67, 66b
 training model, 57
 well-being, 46
- Parent assessment, in adolescents, 164
- Parenteral agents, for juvenile idiopathic arthritis, 692–693
- Parent-focused interventions, 57
- Parenting
 challenges, 64–68
 essential, 50
 social and emotional strategies and, 54
 strategies to promote family functioning, 51–53, 52b
 style, 46, 59
- Parenting Pyramid, 51
- Parents' Assessment of Protective Factors (PAPF), 34–35
- Parents' Evaluations of Developmental Status (PEDS), for infants, 113t
- Parietal lobe, 875t
- Parinaud oculoglandular syndrome, 648
- Paromomycin, for intestinal parasites, 607t
- Paronychia, 720–721, 721f
- Partial-thickness burns, 349, 351b
- Particulate matter, as air pollutant, 22t
- PAS. *See* Pediatric Asthma Questionnaire
- Passive immunity, 265
- Passive range of motion, 844–845
- Patch, 712b
- Patella, dislocation of, 864t–865t
- Patellofemoral pain syndrome, 871t
- Patent ductus arteriosus, 550–551, 550f
- Pathologic headaches, red flags suggestive of, 883b
- Patient- and family-centered care (PFCC), 3
- Patient and family education, in respiratory system, 509b, 510
- PCOS. *See* Polycystic ovary syndrome
- PCV13. *See* Pneumococcal conjugate vaccine 13
- Pectus carinatum, 531–532, 531
- Pectus deformities, 531–532
- Pectus excavatum, 531
- Pediatric assessment, 31–32
 basic principles of, 31
 health supervision, surveillance, and screening in, 32
 history, 32, 33b
 measurement in, 31–32
 growth charts, 31–32
 physical examination, 32, 34b–35b, 35f
- Pediatric Asthma Quality of Life Questionnaire (PAQLQ), 663
- Pediatric Asthma Questionnaire (PAS), 663
- Pediatric dietary guidelines, 171
- Pediatric Environmental Health Specialty Units (PEHSU), 15
- Pediatric health, environmental influences on, 12–26
 epidemiologic model of environmental health hazards, 15–23
 principles of, 12–15, 13t–14t
- Pediatric injury prevention, 299–305, 300t
 common injury mechanisms of, 301–303
 drowning, 302
 falls, 302
 fires and burns, 302–303
 motor vehicle-related injuries, 301–302, 301f
 poisoning, 303
- Pediatric injury prevention (*Continued*)
 gun violence prevention, 304
 intimate partner violence, 304
 unintentional injuries, 299–304
 violence, 303–304, 303b
- Pediatric medical home, 1, 368–369
- Pediatric nurse practitioner, then and now, 3
- Pediatric pain, 329
 assessment of, 331–333, 332t
 behavioral indicators in, 333b
 laboratory and imaging studies in, 333
 physical examination for, 332–333, 333b
 history, 331–332, 332b
 management of, 333–334, 333t
 after procedure, 334, 338b
 barriers to, 330–331
 factors influencing, 329–330
 health care providers, 331
 health care systems, 331
 nonpharmacologic measures in, persistent, 335
 in palliative care, 370
 patient and family, 331
 persistent, 334–335
 pharmacologic considerations in, 333, 334t, 335b
 pharmacologic measures in, persistent, 334–335
 physiologic factors influencing, 329
 procedural, 334, 338b
 before procedure, 334, 335b, 336t–337t
 during procedure, 334
 social-emotional factors influencing, 329–330
 overview of, 329
 partnership in care and, 335–337
- Pediatric palliative care, 365–375
 after death of child, 373
 barriers to, 373
 benefit from, 367t
 care coordination for, 372–373
 care delivery for, 372–373
 communication for, 369f
 components of, 366f
 epidemiology of, 366–367
 funding/insurance coverage for, 372–373
 interdisciplinary team in, 365–366, 367b
 levels of, 365
 principles of, 366b
 referral for, 368b
- Pediatric primary care, 1–5, 2f
 additional resources on, 5
 for Children and Youth with Special Healthcare Needs, 4–5
 issues in, 3–4
 lifelong impact of protective and adverse childhood experiences, 3–4
 transition to adult care, 4
 two-generation or dual patient, 3
 primary prevention *versus*, 1–3, 2f
- Pediatric primary care providers (PCPs), 3
- Pediatric Research Equity Act (PREA), 322

- Pediatric respiratory system, 504–505
- Pediatric sleep cycle, 206
- Pediatric Sleep Practices Questionnaire (PSPQ), 211, 212t
- Pediatric vasculitis, 699–702
 - immunoglobulin A vasculitis, 700–701
 - Kawasaki disease, 701–702
- Pediculicides, 714, 736
- Pediculosis, 734–737, 736t
- Pediculosis capitis, 735
- Pediculosis corporis, 735
- Pedigree, for congenital and inherited disorders, 380–381, 381t, 382f–383f
- PEDS. *See* Parents' Evaluations of Developmental Status
- PEHSU. *See* Pediatric Environmental Health Specialty Units
- Pelvic inflammatory disease, 966, 966b
- Pelvic pain, 949–951
 - acute, 949–950, 949b
 - chronic and recurrent, 950–951, 950b
- Penetrance, definition of, 378t
- Peptic ulcer disease (PUD), 579–581
 - clinical findings of, 579–580
 - complications of, 580
 - diagnostic studies of, 580
 - differential diagnosis of, 580
 - history of, 579–580
 - management of, 580
 - patient and family education in, 581
 - physical examination of, 580
- Perception, of pain, 329
- Perfluorinated compounds, as endocrine disruptor, 23t–24t
- Perforated tympanic membrane, 499f, 500
- Pericarditis, 562, 616
- Pericoronitis, 293
- Perinatal complications and injuries, 395–396
- Perinatal disorders, common neonatal conditions in, neonatal abstinence syndrome, 414, 415f
- Period of PURPLE crying, 105, 110, 111f
- Periodic limb movements, 211
- Periodontal diseases, 290
- Periorbital cellulitis, 478, 478f
- Periosteum, in fracture healing, 843
- Peripheral nervous system (PNS), 874, 875f–876f, 875t
- Peristalsis, 566
- Periumbilical pain, 567
- Permanent teeth, 283
- Permethrin, 736
- Peroxisomal disorders, 835t
- Persistent asymptomatic proteinuria, 918
- Persistent diarrhea, 602
- Pertussis, 519–520, 519t
 - care of exposed children, 520
 - clinical findings of, 519–520
 - complications of, 520
 - diagnostic studies of, 519–520
 - differential diagnosis of, 520
 - management of, 520
 - prevention of, 520
- Pes planus, 863–865
- Pesticides, 361–363
- Pesticides, as endocrine disruptor, 23t–24t
- Phagocytosis, 504
- Pharmaceuticals
 - disposal of, 324
 - labeling of, 320
 - manufacturers of, supply issues with, 320–321
 - off-label prescribing of, 321–322
 - regulation and safety of, 320–321
- Pharmacologic testing (PGx testing), for congenital and inherited disorders, 385
- Pharyngitis, 513–515
 - clinical findings of, 513
 - complications of, 514–515
 - diagnostic studies of, 513–514
 - history of, 513
 - management of, 514
 - physical examination of, 513
- Phenylketonuria, 835t, 836
- Phenytoin, ocular side effects of, 464t
- Phimosis, 932
- Phosphodiesterase-4 inhibitor, for atopic dermatitis, 688
- Phosphorus, 176, 177t
- Photoscreening, 461
- Phototherapy, for atopic dermatitis, 689
- Phthalates, as endocrine disruptor, 23t–24t
- Physical fractures, 843
- Physical abuse, 308–311
 - child and family medical history, 309
 - child medical history, 309
 - clinical findings of, 308–309, 309b
 - diagnostic studies of, 310
 - differential diagnosis of, 309–310
 - family medical history, 309
 - management strategies of, 310–311
- Physical activity, 231–264
 - for children and adolescents, strategies to support, 234–238
 - counseling families, 235
 - injury prevention, 236, 237t–238t
 - intentional weight loss and weight gain, 236–238
 - lifestyle behaviors, health care providers influence on, 235
 - preseason conditioning, 236
 - strength training, 235–236, 236b
 - climate and environment, considerations of, 238–239
 - dehydration in, 239
 - ergogenic drugs and supplements in, 244–245, 244b–245b
 - guidelines for, 232
 - health benefits for, 232
 - heat illness and, prevention of, 239
 - heat in, humidity and, 238–239
 - nutrition and supplements in, performance enhancing, 242–245, 243t
 - overview of, 231–232
 - preparticipation physical examination for, 245–251, 246t–250t
- Physical activity (*Continued*)
 - components of, 250–251, 252f, 253t, 253b
 - diagnostic studies for, 251
 - health history for, 250–251, 251b
 - liability issues, 250
 - medical clearance, 250
 - physical examination and, 251
 - promotion of, socioecological model for, 234t
 - recreational activities and, 239–241, 240t–241t
 - with special health care needs, 232–233
 - standards for, 232
- Physical development
 - in adolescence, 153–156, 154f
 - female stages, 153–156, 155f
 - male stages, 156, 156f
 - in early adolescence, 166
 - in early childhood, 120, 130
 - in infants, 103, 105, 106t–108t
 - in late adolescence, 168
 - in middle adolescence, 167
 - in middle childhood, 139, 140t
 - of newborns, 93
- Physical examination
 - of abdominal migraine, 574
 - of acute diarrhea, 601
 - of anal fissures, 591
 - of appendicitis, 582–583
 - in assessment of nutritional status and, 176
 - of asthma, 665, 665t
 - of chronic diarrhea, 606
 - of Crohn disease, 592
 - of cyclic vomiting syndrome, 572
 - of dysphagia, 569
 - of foreign body ingestion, 581
 - of functional abdominal pain-not otherwise specified, 586
 - of gastroesophageal reflux disease, 574
 - of gastrointestinal disorders, 567
 - of growth faltering, 595–596
 - of immunoglobulin A vasculitis, 700
 - of infantile hypertrophic pyloric stenosis, 577
 - for infectious disease, 613
 - of intestinal and rectal polyps, 590
 - of intussusception, 583
 - of irritable bowel syndrome, 587
 - of juvenile fibromyalgia syndrome, 696
 - of juvenile idiopathic arthritis, 691
 - of malabsorption syndromes, 589
 - in middle childhood, 147–150
 - in cognitive development, 148t–150t
 - in communication and language development, 148t–150t
 - in emotional development, 148t–150t
 - in motor development, 148t–150t
 - in physical development, 148t–150t
 - in social development, 148t–150t
 - of myalgic encephalomyelitis/chronic fatigue syndrome, 697
 - in newborns
 - following stabilization, 93, 96t–97t
 - immediately after birth, 92–93

- Physical examination (*Continued*)
of nonpolio enteroviruses, 616
of peptic ulcer disease, 580
of primary immunodeficiency disorder, 704
for sleep, 210–211
of systemic lupus erythematosus, 694
of ulcerative colitis, 593
of vomiting and dehydration, 570
- Physical growth
in early childhood, 120
in infants, 103, 105, 106t–108t
in middle childhood, 139, 140t
in newborns, 93
- Physical therapy, for orthopedic injury, 849
- Physiologic laid-back position, for
breastfeeding, 197, 197f
- Physis, 841
- Phytophotodermatitis, 743
- Piaget, Jean, 86, 86t
- Piaget's theory, 86, 86t
- PIDD. *See* Primary immunodeficiency disorder
- Piercings, and dental health, 295
- Pigment lability, 709–710
- Pigmented nevi, 756–759, 757b
- Pill-induced amenorrhea, 959
- Pineal gland, 800t
- Pinworm. *See* Enterobius vermicularis
- Piperazine, for allergic rhinitis, 683t
- Piperidine, for allergic rhinitis, 683t
- Pirbuterol, for asthma, 677t–678t
- Pits, in newborn, 98
- Pituitary gland, 800t
- Pityriasis alba, 761, 761f
- Pityriasis versicolor, 728–729
- Plant oleoresins, 743
- Plantar fasciitis, in physical activity, 237t–238t
- Plantar warts, 734, 734f
- Plaque psoriasis, 753–754
- Plasma, 767
- Platelet cells, 770
- Platelet count, in infectious disease, 613
- Platelet disorders, 788–791
bleeding history, 788
diagnostic studies for, 788
hemophilia A, 789–791, 790t
hemophilia B, 789–791, 790t
immune thrombocytopenia, 788–789
pancytopenia, 791
thrombophilia, 791
von Willebrand disease, 789–791, 790t
- Play and peer relationships, in early
childhood, 123
- Play audiometry, 488t
- Pleiotropy, definition of, 378t
- Pleural effusion, causes of, 654
- Pleurodynia, 616
- Plumbism, 780–781
- PNES. *See* Psychogenic nonepileptic seizure
- Pneumatic otoscopy, 487
- Pneumococcal conjugate vaccine 13 (PCV13;
Pevnar 13), 267
- Pneumococcal vaccine, 278, 279b
- Pneumonia, 525–527
clinical findings in infants and young
children, 525–526
diagnostic studies of, 526
differential diagnosis of, 526
management of, 526–527
microorganisms, age variants in, 526t
physical examination of, 526
various forms of, 525t
- PNS. *See* Peripheral nervous system
- Poisoning, 303
acute pediatric, 359, 359b
- Polio vaccine, 278
- Poliovirus infections, 617
- Pollution, ambient air, 21
- Polyarthritis, acute rheumatic fever and, 697
- Polybrominated diphenyl ethers (PBDEs), as
endocrine disruptor, 23t–24t
- Polycystic kidney disease, 404
- Polycystic ovary syndrome (PCOS), 810–811,
811t, 947
- Polycythemia, 405–406
- Polydactyly, 408
- Polyps, intestinal and rectal, 590–591
- Pons, 875t
- Poor weight gain, 203–204
- POP. *See* Progestin-only pills
- Popliteal cysts, 872
- Port-wine stains, 756
- Positional molding, unilambdoid synostosis
and, 902f
- Positions, for breastfeeding, 195–197
cradle position and cross-cradle position,
195, 195f–196f
football hold, 196, 196f
physiologic laid-back position, 197, 197f
principles of, 195, 195f
side-lying position, 196, 196f
- Positive stress, 41t
- Postlicensure Rapid Immunization Safety
Monitoring System (PRISM), 273
- Postpartum depression, 111, 112f
- Postpartum psychiatric disorders, 110–111
- Postpartum psychosis, 111
- Poststreptococcal GN (PSGN), 921
- Poststreptococcal reactive arthritis
(PSRA), 699
- Posttraumatic stress disorder (PTSD),
426–427, 426t
clinical findings of, 426–427
differential diagnosis of, 427
management of, 427
- Posture, assessment of, 845
- PPE. *See* Preparticipation physical
examination
- PPI. *See* Proton pump inhibitor
- Prader Willi syndrome (PWS), clinical
findings and primary care issues of,
386t–390t, 391f
- PREA. *See* Pediatric Research Equity Act
- Preauricular skin tags, in newborn, 98
- Prebiotics, 568
- Precocious puberty, 806–808, 807f, 807b
clinical findings in, 807–808
diagnostic studies in, 808
history in, 808
management of, 808
physical examination of, 808
- Preconception, environmental risk factors for,
13t–14t
- Preconceptional counseling, 961, 961b
- Prediabetes, 823–827
- Predictive tests, for congenital and inherited
disorders, 385
- Preeruption cysts, 286
- Pregnancy
contraindications and precautions in, 269
early
physiology of, 939, 941f
symptoms in, 941b
ectopic, 961
high-risk, 395, 396b
invalid contraindications and precautions
in, 270–271
sports and, 247t–250t
teen, 960–961
after diagnosing, 960–961
diagnosis of, 954f, 960
preconceptional counseling, 961, 961b
- Premature and special needs newborns, 396,
398b
- Premature births, healthcare system and, 29
- Prenatal screening, for congenital and
inherited disorders, 384
- Prenatal stage, environmental risk factors for,
13t–14t
- Prenatal system, growth faltering and, 595t
- Preparticipation physical examination (PPE),
for physical activity and sports, 245–251,
246t–250t
components of, 250–251, 252f, 253t, 253b
diagnostic studies for, 251
health history for, 250–251, 251b
liability issues, 250
medical clearance, 250
physical examination and, 251
- Prepubertal vaginal bleeding, 943
- Prepubertal vulvovaginitis, 941–942, 942t
- Preschoolers
in early childhood, 129
elimination pattern in, 217t
environmental risk factors for, 13t–14t
patterns of sexuality in, 72
posttraumatic stress disorder symptoms in,
426t
sexual behaviors, self-concept, and
relationships of, 73t
urinary tract infections in, 911t
- Prescribing medications, 320–328
factors to consider in, 322–324
general guidelines for, 321–322
guidelines for writing, 324–325, 325b
medication adherence and, 322–324, 323t
National Safety Goals regarding, 320
in pediatrics, 321

- Pressure-equalizing tubes, 499–500
- Presymptomatic tests, for congenital and inherited disorders, 385
- Preterm birth, invalid contraindications and precautions in, 271
- Prevacid. *See* Lansoprazole
- Pevnar 13. *See* Pneumococcal conjugate vaccine 13
- Primarily hepatitis C, sports and, 247t–250t
- Primary care provider
in holistic care, 367–372
communication, 368–370, 369f, 369t
referral, 367–368, 368f, 368b
symptom management, 370–372
pediatric environmental risk factors and, 13t–14t
- Primary closure, 348
- Primary health care management strategies, 541–544, 543b, 544t
- Primary immunodeficiency disorder (PIDD), 702–704
clinical presentation of, 703t, 704
diagnostic studies of, 704
history of, 704
management of, 704
physical examination of, 704
warning signs of, 704b
- Primary lactase deficiency, 588
- Primary prevention, 1–3
- Primary tooth, 283
- Primary ulcers, 579
- PRISM. *See* Postlicensure Rapid Immunization Safety Monitoring System
- Probiotics, 568
for diarrhea, 601
for respiratory disorders, 509–510
for ulcerative colitis, 594
- Procalcitonin, in infectious disease, 613
- Progestin-only pills (POP), 959
- Prolonged diarrhea, 602
- Promotive factors, 41–43
- Prophylaxis, for urinary tract infections, 914b
- Propionic acidemia, 835t
- Propranolol, for migraine, 886t
- Protective factors, 41–43
in family assessment, 34–35
peptic ulcer disease and, 579
- Protein
absorption, in GI tract, 566
for athletes, 242, 243t
in human milk, 192
- Protein-energy malnutrition, 594
- Proteinuria, 918–920
clinical findings of, 918
diagnostic studies for, 918
differential diagnosis of, 918
management of, 918–920, 919f
patient and family education for, 920
physical examination of, 918
prevention of, 920
prognosis of, 920
- Protonix. *See* Pantoprazole
- Proximal humeral epiphysiolysis, 871t
- Pseudohypoparathyroidism, 817
- Pseudomonas aeruginosa*, 529
- Psoriasis, 745t
- Psoriasis vulgaris, 753
- PSRA. *See* Poststreptococcal reactive arthritis
- Psychodynamic theories, 84–86
psychoanalytic theorists, 85–86
psychosexual theory, 84–85
psychosocial theory, 85, 85t
- Psychogenic nonepileptic seizure (PNES), 893
- Psychogenic pain, 330b
- Psychosis, postpartum, 111
- Psychosocial screening tools, 307b
- Psychosocial system, growth faltering and, 595t
- PTSD. *See* Posttraumatic stress disorder
- Pubertal development
disorders of, 806–808, 807b
delayed puberty, 808–809, 808b
precocious puberty, 806–808, 807f, 807b
menstrual cycle and, 938–939
- Pubertal suppression, 809–810, 809b
- Puberty, 153, 154f
- Pubic lice, 735
- Public confidence, vaccine and, 273
- PUD. *See* Peptic ulcer disease
- Pulmonary compromise, sports and, 247t–250t
- Pulmonary defense, alterations in, 505–506
- Pulmonary function testing (spirometry), for asthma, 665, 666t, 666b
- Pulmonary system
effect of cystic fibrosis on, 529
growth faltering and, 595t
- Pulmonic stenosis, 554
- Pulse oximetry, 508
- Pulses, 538
- Puncture wounds, 346–347, 347t
- Purines, 878t
- PURPLE crying, period of, 105, 110, 111f
- Purpura, 712b
- Pustule, 712b
- PWS. *See* Prader Willi syndrome
- Pyarthrosis, in puncture wounds, 346
- Pyelonephritis, 910–913
- Pyloric stenosis, 401
- Pyogenic granuloma, 290
- Pyrantel pamoate (Reese's pinworm), for intestinal parasites, 607t
- Pyrethrin, for pediculosis, 736
- Pyrilamine, for allergic rhinitis, 683t
- Q**
- Quadriceps contusion, 864t–865t
- Quetiapine, ocular side effects of, 464t
- Quick-start contraception, 955, 955b
- R**
- Rabies immune globulin, 619t–621t
- Racism, in healthcare, history of, 27–28
- Radiography
for gastrointestinal disorders, 568
for musculoskeletal system, 846–847
- Radiologic workup, for urinary tract infections, 914t, 914b
- Radon, as air pollutant, 22t
- Rales, 505
- Range of motion, examination of, 844–845
- Ranula, 293, 294f
- Rapid eye movement (REM), 207–208
- Raynaud phenomenon, sports and, 247t–250t
- Reactive erythema, 746–752
angioedema, 749–751
drug eruptions, 748t
drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), 748–749
erythema multiforme, 750f, 751–752
morbiform drug eruptions, 747–748
Stevens-Johnson syndrome, 751–752, 751f
toxic epidermal necrolysis, 751–752
urticaria, 749–751, 749f
- Receptors, in epidemiologic model, 15
- Recombinant vaccines, 266
- Recreational activities, safety measures of, 239–241, 240t–241t
- Rectal foreign bodies, 581
- Rectal polyps, 590–591
- Recurrent abdominal pain, 585–586
- Recurrent epistaxis, 522–523
- Recurrent headaches, sports and, 247t–250t
- Recurrent pelvic pain, 950–951, 950b
- Recurrent physical symptoms, of stress, 63
- Recurrent plexopathy, sports and, 247t–250t
- Red blood cells (RBCs). *See* Erythrocytes
- Red flags
for chronic renal failure, 916b
genetic, 381, 384t
- Red reflex, 460
- Reese's pinworm. *See* Pyrantel pamoate
- Referral
in cardiovascular disorders, 544
mental health and, 58
pediatric palliative care, 367–368, 368f, 368b
to urologist, 910
- Referred pain, 567
- Reflex
corneal light, 460–461
defecation, 566
let-down, 193
milk ejection, 193
red, 460
- Refractive errors, 466, 466b
- Regulation
in early childhood, 132–133
in infants, 111–117
- Regurgitation, 569
- Rehabilitation, 2
- Rehydration therapy, 572t
- Relactation, induced, 192
- Relationships
attachment and, 43–44
temperament, 43
connectedness and developmental, 44, 44t
difficulties in, 59
safe, stable, nurturing, 43

- Remarriage, 64–66
- Renal conditions, neonatal, 403–405
 - acute renal failure, 403
 - hydronephrosis, 404
 - neuroblastoma, 404
 - polycystic kidney disease, 404
 - renal agenesis, 405
 - renal artery or vein thrombosis, 404
- Renal failure, chronic, red flags for, 916b
- Renal system, growth faltering and, 595t
- Renal tubular acidosis (RTA), 923
- Reproductive system, effect of cystic fibrosis on, 530
- Resilience, 42b, 45, 45f
- Respiratory disorders, 503–535
 - adenoidectomy for, 515
 - bacterial tracheitis, 515
 - bronchiolitis, 523
 - croup, 515–517, 516t
 - differentiating from, 516t
 - epiglottitis, 517–518
 - foreign body aspiration, 521–522, 522f
 - pathophysiology of, 505
 - sports and, 247t–250t
 - tonsillectomy for, 515
 - upper respiratory tract
 - common cold, 510, 511t
 - diphtheria, 518–519
 - infection, 510, 511t
 - nasal foreign body, 520–521
 - nasopharyngitis, 513
 - pertussis, 519–520, 519t
 - pharyngitis, 513–515
 - recurrent epistaxis, 522–523
 - rhinosinusitis, 510–513
 - tonsillitis, 513–515
 - tonsillopharyngitis, 513–515
- Respiratory failure, 506
- Respiratory problems, in children with
 - cerebral palsy, 896
- Respiratory rate, 538–539
- Respiratory syncytial virus immune globulin, 619t–621t
- Respiratory system
 - airway generations and structure, 503
 - assessment of, 506–508
 - diagnostic studies of, 508
 - history of, 506
 - physical examination of, 506–508, 507t
 - basic management strategies for, 508–510
 - antibiotic stewardship in, 510
 - general measures, 508–509
 - medications for, 509–510
 - patient and family education, 509b, 510
 - defense systems of, 505–506
 - differentiating from similar diseases of, 516t
 - mechanics of breathing, 503–504
 - pediatric, 504–505
 - pulmonary anatomy of, 503
 - pulmonary defense, 504
- Restless legs syndrome, 211
- Restrictive processes, in respiratory system, 505
- Resuscitation, in delivery room, 397f
- Reticulocyte count, 767
- Reticulocytes, 767
- Retinal detachment, 482
- Retinoblastoma, 470–471
- Retinoids, 740–741
- Retinopathy of prematurity (ROP), 398, 469–470
- Rett syndrome, 906–907
- Reye syndrome, 904–905
- Rheumatic fever, acute, 697–699
 - clinical findings of, 697–698, 698b
 - complications of, 699
 - diagnostic studies of, 698
 - differential diagnosis of, 698–699
 - history of, 697–698
 - management of, 699
 - primary and secondary prevention of, 699
- Rheumatoid factor, for autoimmune disease, 661t
- Rheumatologic diseases, sports and, 247t–250t
- Rheumatologic disorders, 690–699
 - acute rheumatic fever, 697–699
 - juvenile fibromyalgia, 695–696, 695b
 - juvenile idiopathic arthritis, 690–693
 - myalgic encephalomyelitis/chronic fatigue syndrome, 696–697
 - pathophysiology and defense mechanisms of, 660, 661t
 - poststreptococcal reactive arthritis, 699
 - systemic lupus erythematosus, 693–695
- Rhinosinusitis, 510–513
 - clinical findings of, 512
 - complications of, 512–513
 - diagnostic studies of, 512
 - differential diagnosis of, 512
 - management of, 512
 - prevention of, 513
- Rickettsia rickettsii*, 644
- Right-to-left shunting, 551–553
- Ringworm, 723
- Risk, in epidemiologic model, 15
- Risk characterization, in epidemiologic model, 15
- Risk factors, 41–43
- Risk-taking behavior, in adolescents,
 - 159–161, 160b, 161t
 - self-injurious behaviors, 162–163
 - technology and social media use, 168
 - tobacco use, 161–162, 162t
- Ritter disease, 718
- Rituals, family functioning and, 47
- Rocky Mountain spotted fever, 644–645
- ROP. *See* Retinopathy of prematurity
- Roseola infantum (exanthem subitum), 625, 625f
- Rotavirus, 598t–600t
 - vaccine, 280
- Roundworm. *See* *Ascaris lumbricoides*
- Routine, family functioning and, 47
- Routine well-child encounter, 32
- RTA. *See* Renal tubular acidosis
- Rubella, 635–636
 - clinical findings in, 636
 - congenital, 411
 - diagnostic studies for, 636
 - differential diagnosis, management, and complications, 636
- S**
- Saccharomyces*, 568
- Safe sleep, 111–115
- Safety
 - in early childhood, 133–134
 - in middle childhood, 144t–146t, 146
 - in newborn, 100, 101f
- Saliva, examination of, 285
- Salmon patches, 756
- Salmonella* spp., 598t–600t
- Salter-Harris classification, 843–844, 843f
- Sapovirus, 639
- SBP. *See* School Breakfast Program
- Scabicides, 714
- Scabies, 737–739, 738f
- Scald burns, 349
- Scales, 712b
- Scalp
 - medications for, 714
 - psoriasis, 754
- Scar, 712b
- Scarification, 764–765
- Scarlet fever, 650
- SCD. *See* Sudden cardiac death
- SCFE. *See* Slipped capital femoral epiphysis
- Scheuermann kyphosis, 855
- School adjustment, during middle childhood, 142–143, 144t–146t
- School-age children
 - elimination pattern in, 217t
 - patterns of sexuality, 72–74
 - posttraumatic stress disorder symptoms in, 426t
 - sexual behaviors, self-concept, and relationships of, 73t
 - urinary tract infections in, 911t
- School Breakfast Program (SBP), 9–10
- School refusal, in middle childhood, 143, 144t–146t
- SCID. *See* Severe combined immunodeficiency
- Scintigraphy, 846–847
- SCIT. *See* Subcutaneous immunotherapy
- SCN. *See* Suprachiasmatic nucleus
- Scoliosis, 532, 853–855, 854t
 - clinical findings of, 853–854
 - complications of, 855
 - differential diagnosis of, 854
 - management of, 855
 - prevention of, 855
- Scorpions, bites and stings of, 355–356
- SCREEM (Social, Cultural, Religious, Economic, Education, and Medical resources), in family assessment, 34

- Screening
 in adolescents, 164
 for congenital and inherited disorders, 383–384
 for contraindications and precautions, in vaccination, 271–272, 275
 developmental, for infants, 113t, 118
 in early childhood, 130, 131t–133t
 in middle childhood, 150, 151t
 in pediatric assessment, 32
 in pediatric health supervision, 98–99
- Screening audiometry, 488t
- Scrotum
 hydrocele and, 927
 trauma to, 930
- Scrubbing, of wounds, 345
- SCT. *See* Sickle cell trait
- SDGs. *See* Sustainable Development Goals
- SDM. *See* Shared decision making
- Sealants, for tooth decay, 288, 288f
- Sebaceous glands, anatomy, 709
- Sebaceous hyperplasia, in newborn, 99t
- Seborrhea, 745t
- Secondary immunodeficiency disorder, 703–704
- Secondary lactase deficiency, 588
- Secondary prevention, 2
- Secondary ulcers, 579
- Sedimentation rate, for autoimmune disease, 661t
- Segmental lengths, BM–APP
- Seizure disorder, sports and, 247t–250t, 254–255
- Selective IgA, clinical presentation of, 703t
- Selective screening, 32
- Selective serotonin reuptake inhibitors (SSRIs), ocular side effects of, 464t
- Self-care, in early childhood, 133–134
- Self-control, in early childhood, 121–123
- Self-monitor blood glucose (SMBG), 825–826
- Self-regulation, 45, 54
- Self-report, of pain, factors that influence, 331
- Semantics, in early childhood, 126–127
- Sensory development, of infants, 106t–108t
- Sensory processing, difficulties with, 62–63, 63b
- Separation, 64–66
- Separation anxiety disorder, 421–422
- Sepsis, neonatal, 410, 411b
- Septic arthritis, limping and, 869t–870t
- Serial measurements, in pediatric assessment, 31–32
- Serotonin (5-HT), 878t
- Serum ferritin, for autoimmune disease, 661t
- Serum immunoglobulin G (IgG) antibody titer, for *Helicobacter pylori*, 580
- Sever disease, 871t
- Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), 639–640
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 640
- Severe combined immunodeficiency (SCID), clinical presentation of, 703t
- Severe engorgement, 202
- Sex counseling, contraceptive and, 78–80
- Sex development, disorders of, 805–806, 806b
- Sexual abuse, 311–314, 311b
 clinical findings of, 311–312, 312f
 diagnostic studies of, 312–313, 313t
 differential diagnosis of, 313
 management strategies of, 313–314
- Sexual behaviors, factors that can alter, 80–81
- Sexual function, 71
- Sexual health, 71
- Sexual maturity rating (SMR), 153–156
- Sexual orientation, 77
 definition of, 71–72
 management of, 81, 82b
- Sexual relationships, 71
- Sexual self-concept, 71
- Sexuality
 assessment of, 74–75
 confidentiality and, 75
 contemporary definitions of, 70–72
 contraceptive, 78–80
 counseling of the adolescent, 78
 cultural context of, 70
 factors that can alter, 80–81
 fostering healthy, 75–80
 gender identity and, 70–82, 71f
 history, 75
 approach to, 75
 comprehensive adolescent, 76b
 problem-focused adolescent, 77b
 types of, 75, 77b
 patterns of, 70–74
 physical examination, 75
 safer sex counseling, 78–80
 stages of developmental patterns of, 72–74, 73t
 early adolescence, 74
 early childhood (1-2 years old), 72
 infancy (birth-1 year old), 72
 late adolescence, 74
 middle adolescence, 74
 middle childhood (6-10 years old), 72–74, 74b
 preschool (3-5 years old), 72
- Sexuality education, 77–78, 79b
 criteria of, 80b
- Sexually transmitted infections, 413–414, 961–966
 adolescent health disparity, 961, 962t
 chlamydia, 413
 common, 962, 964f
 gonorrhea, 413
 human immunodeficiency virus, 414
 pelvic inflammatory disease, 966, 966b
 prevention and screening, 961, 963t, 963b
 syphilis, 413
 treatment and counseling, 963, 963b, 964t–965t
- Shaft fractures, 844
- Shaken baby syndrome, 105, 310
- Shared decision making (SDM), in pediatric and family assessment, 35–36, 36f
- Shigella* spp., 598t–600t
- Shin splints, 871t
 in physical activity, 237t–238t
- Shingles, 625, 731–732
- Shoes, therapeutic, 848–849
- Short-acting β_2 -agonists, for asthma, 677t–678t
- Short-bowel syndrome, sports and, 247t–250t
- Shyness, 59
- Sibling rivalry, in early childhood, 127–128, 128b
- Sickle cell anemia, 785–787
 clinical findings of, 785
 complications of, 786–787
 diagnostic studies for, 785
 differential diagnosis of, 785–786
 management of, 786
 patient and family education of, 787
 physical examination in, 785
- Sickle cell disease (SCD), 785–787
 sports and, 247t–250t
- Sickle cell trait (SCT), 785–787
 sports and, 247t–250t, 255
- Side-lying position, 196, 196f
- SIDS. *See* Sudden infant death syndrome
- Silent carrier state, 782
- Single ventricle defects, 552–553, 553f
- Single-gene disorders, 376–379
- Sinuses, anatomy and physiology of, 503
- Sinusitis, acute bacterial, 511
- Sitting height, 968f, 969
- SJS. *See* Stevens-Johnson syndrome
- Skeletal injuries and fractures, in physical abuse, 309
- Skill acquisition, 54
- Skill fluency, 54
- Skin
 appendages of, 709
 conditions, in newborn, 97–98, 98f, 99t
 lubrication, for atopic dermatitis, 689
 trauma to, 345–352
- Skin barrier, repair and treatment of, 688
- Skin glue, 348
- Skin infections, sports and, 247t–250t, 255–257, 256t, 256b
- Skin problems, with cerebral palsy, 897
- Skinner, B.F., 87, 88t
- SLE. *See* Systemic lupus erythematosus
- Sleep, 206–215, 207f
 assessment of, 210–211
 common disorders of, 211–214
 anxiety, 213–214
 attention-deficit/hyperactivity disorder, 214
 autism spectrum disorder, 213
 central sleep apnea, 213
 obstructive sleep apnea, 213
 parasomnias, 211–213
 periodic limb movements, 211
 restless legs syndrome, 211
 sleep-disordered breathing, 213

- Sleep (*Continued*)
 cycle of, 206–208, 207f
 developmental sleep considerations,
 208–210
 adolescence, 209–210
 early childhood, 208–209, 208t
 middle childhood, 208t, 209
 newborns and infants, 208, 208t
 in middle childhood, 144–146, 147t
 patterns, 208–210, 208t
 science of, 206
- Sleep aids, for atopic dermatitis, 688
- Sleep development, of infants, 106t–108t
- Sleep paralysis, 894
- Sleep-awake patterns
 in early childhood, 132–133
 in infants, 111–117
- Sleep-disordered breathing, 213
- Slipped capital femoral epiphysis (SCFE),
 858–860, 859f
 clinical findings of, 858
 complications of, 860
 differential diagnosis of, 858
 limping and, 869t–870t
 management of, 860
 prevention of, 860
- SLIT. *See* Sublingual immunotherapy
- SMBG. *See* Self-monitor blood glucose
- Smokeless tobacco, 295–296
- SMR. *See* Sexual maturity rating
- Snakebites, 356–357
- SNAP. *See* Supplemental Nutritional Assistance Program
- Social cognition, 87, 87b
- Social competence, in early childhood, 121
- Social development, 44, 157–159, 158t, 159b
 in early adolescence, 166
 in early childhood, 120–123, 130
 in infants, 106t–108t, 109, 114–117
 in late adolescence, 168
 in middle adolescence, 167
 in newborns, 93
- Social difficulties, 59–60
- Social growth, in early childhood, 134–135
- Social learning, 87–88
- Social media use, by adolescents, 163–164
- Social needs, in palliative care, 371
- Social transitions, of adolescence, 157
- Social-emotional development, mental health and, 44–45, 45f
- Soft tissue, trauma to, 345–352
- Solid food, introduction of, 181, 183b
- Solitary polyps, 590
- Somatic pain, 330b
- Sore nipples, 201–202
- Sparks, 54
- Special education, in children with cerebral palsy, 897
- Special Supplemental Nutrition Program for Women, Infants, and Children (WIC), 9–10
- Specific gravity, 909
- Specific learning disorders (SLD), 441–443
 clinical findings and assessment of, 441
 definition and diagnostic criteria for, 441, 443b
 diagnosis, screening and specialty referral for, 441–442, 442b
 follow-up and referral of, 443
 management of, 442–443, 442t
 behavior management and counseling, 442–443
 educational system and adaptive supports, 443
 family education and support, 442, 448b
- Specific protection, in primary prevention, 1
- Spermatocoele, 928
- Spiders, bites and stings of, 355
- Spina bifida, 899
- Spinal cord, 875t
- Spinal muscular atrophy, 898
- Spinal nerves, functions of, 875t
- Spine trauma, sports and, 247t–250t
- Spinosad, 736
- Spiritual development, 44–45, 45f
- Spiritual needs, in palliative care, 371–372
- Spirometry. *See* Pulmonary function testing
- Spitz nevus, 757b, 758–759, 759f
- Spleen, enlarged, sports and, 247t–250t
- Splenectomy, for hereditary spherocytosis, 787
- Splints, care of children in, 849
- Spontaneous otoacoustic emissions, 487
- Sports, 231–264
 absence of paired organs and, 258
 acute upper respiratory infection and, 247t–250t
 blood-borne viral pathogens, 256–257, 257b
 human immunodeficiency virus, 256–257
 skin infections, 247t–250t, 255–257, 256t, 256b
 chronic health conditions in, evaluation and management of, 247t–250t, 251–257
 asthma, 247t–250t, 251–252
 cardiac conditions, 253–254
 cardiac murmurs, 254
 diabetes mellitus, 247t–250t, 254, 254b
 hypertension, 247t–250t, 254
 seizure disorder, 247t–250t, 254–255
 sickle cell trait, 247t–250t, 255
 classification of, according to contact, 246t
 climate and environment, considerations of, 238–239
 dehydration in, 239
 ergogenic drugs and supplements in, 244–245, 244b–245b
 exercise-induced dyspnea and, 257
 heat illness and, prevention of, 239
 heat in, humidity and, 238–239
 hernia and, 258
 high-risk conditions for, 257–262
 musculoskeletal disorders in, 247t–250t, 258–260
 burners, 259
- Sports (*Continued*)
 concussions, 247t–250t, 259–260, 259b, 260t
 head injury, 259–260
 neck injury, 259
 stingers, 259
 nutrition and supplements in, performance enhancing, 242–245, 243t
 preparticipation physical examination for, 245–251, 246t–250t
 components of, 250–251, 252f, 253t, 253b
 diagnostic studies for, 251
 health history for, 250–251, 251b
 liability issues, 250
 medical clearance, 250
 physical examination and, 251
 recreational activities and, 239–241, 240t–241t
 relative energy deficiency in, 261–262
 specialization in, 235, 235b
 sudden cardiac death and, 257–258
- Sports drinks, energy drinks *versus*, 244
- Sprains, in physical activity, 237t–238t
- SSSS. *See* Staphylococcal scalded skin syndrome
- Stains, for infectious disease, 614
- Standardized screening tools, for sleep, 211, 212t
- Staphylococcal scalded skin syndrome (SSSS), 718, 718f
- Staples, 348
 removal of, 349, 349t
- Status epilepticus (SE), 892
- Sternochondritis, 852
- Steroid therapy, for atopic dermatitis, 687–688
- Stevens-Johnson syndrome (SJS), 751–752, 751f
- Stingers, sports and, 259
- Stings, bites and, 352–357
 animal and human bites, 352–353
 Hymenoptera, 353–354
 mosquitoes, fleas, and chiggers (red bugs or harvest mites), 354–355
 snakebites, 356–357
 spiders and scorpions, 355–356
- Stitches, traditional, 348
- Stool, blood in, 407
- Stool monoclonal antibody test, for *Helicobacter pylori*, 580
- Strabismus, 466–467, 467b
- Strains, in physical activity, 237t–238t
- Stratum corneum, 709
- Strength
 in early childhood, 133
 in infants, 113, 116–117
 promoting, 54
 training, 235–236, 236b
 in children with cerebral palsy, 897
- Strengthening Families, 36–37
- Streptococcal disease, 649–655
 group A, 650–651
 nongroup A or B streptococci, 651

- Stress
 levels of, 41t
 prevent and mitigate effects of, 54–55
- Stress fractures, 871t
 in physical activity, 237t–238t
- Striae, 712b
- Stridor, 516t
- Stromectol. *See* Ivermectin
- Structural scoliosis, 853
- Structural/acquired heart disease, sports and, 247t–250t
- Subacute rhinosinusitis, 511t
- Subconjunctival hemorrhage, 479–480
 physical abuse, 309
- Subcutaneous immunotherapy (SCIT), for
 allergic rhinitis, 684–685
- Subcutaneous injections, various ages for,
 needle lengths and injection sites for, 277
- Subcutaneous nodules, acute rheumatic fever
 and, 698
- Subcutaneous tissue
 assessment of, 710–711
 function of, 709
- Sublingual immunotherapy (SLIT), for
 allergic rhinitis, 684–685
- Substance abuse disorder, 453–454
 clinical findings of, 453–454
 diagnostic studies in, 454
 differential diagnosis of, 454
 management of, 454
- Substance P, 878t
- Subunit vaccines, 266
- Sucking blisters, in newborn, 99t
- Suckling, in infants, 193
- Sudden cardiac death (SCD), 555–556
 clinical findings of, 555–556
 diagnostic studies of, 556
 management of, 556
 sports and, 257–258
- Sudden cardiac event, previous, sports and,
 247t–250t
- Sudden death, family history of, sports and,
 247t–250t
- Sudden infant death syndrome (SIDS), 9
- Sudden unexpected infant death (SUID), 208,
 209b
- Suicide, warning signs for, 429t
- Sullivan, Harry, 85
- Sumatriptan, for headaches, 885t
- Sunblock, 713
- Sunglasses, 463–465
- Sunscreen, 713
- Superficial burns, 349, 351b
- Supernumerary nipples, in newborn, 98
- Supplemental Nutritional Assistance Program
 (SNAP), 9–10
- Supplements, ergogenic drugs and, use of,
 244–245, 244b–245b
- Suprachiasmatic nucleus (SCN), 206
- Suprapubic pain, 567
- Surfactant, 503
- Surgical tape, 348
- Surveillance, developmental, for infants, 118
- Surveillance, in pediatric assessment, 32
- Survey of Wellbeing of Young Children
 (SWYC), for infants, 113t
- Sustainable Development Goals (SDGs), 6, 7f
- Sutton disease, 291
- Sutures, 348
 removal of, 349, 349t
- Sweat glands
 effect of cystic fibrosis on, 530
 types of, 709
- Swimmer's ear, 493
- Swimming, safety measures of, 240t–241t
- SWYC. *See* Survey of Wellbeing of Young
 Children
- Sympathetic system, functions of, 877b
- Symptom analysis, in assessment of mental
 health, 48, 48b
- Symptomatic Wolff-Parkinson-White
 syndrome, sports and, 247t–250t
- Syncope, 563–565, 564t
 clinical findings of, 563–564
 diagnostic studies of, 564
 differential diagnosis of, 564–565
 history of, 563–564
 management of, 564–565
 physical examination of, 564
- Syndactyly, 408
- Syndrome, 381
- Syntax, in early childhood, 126
- Syphilis, 413, 964t–965t
 as newborn infection, 410
- System theories, 88
- Systemic corticosteroids, for asthma, 676t–678t
- Systemic immunomodulating agents, for
 atopic dermatitis, 688–689
- Systemic juvenile idiopathic arthritis (sJIA), 691
- Systemic lupus erythematosus (SLE), 693–695
 clinical findings of, 693–694, 694b
 complications of, 695
 diagnostic studies of, 694
 differential diagnosis of, 694
 history of, 693–694
 management of, 694–695
 physical examination of, 694
 prognosis of, 695
 sports and, 247t–250t
- Systemic problems, in musculoskeletal system,
 842
- T**
- TABS. *See* Temperament and Atypical
 Behavior Scale
- Taenia* (tapeworm), 603t–605t
- Talipes equinovarus, 866
- Tapeworm. *See* *Taenia*
- Tattoos, 764–765
 and dental health, 295
- Tazarotene, for acne, 741
- TBG. *See* Thyroid-binding globulin
- TCIs. *See* Topical calcineurin inhibitors
- Team talk, 35–36
- Technology use, by adolescents, 163–164
- Teen pregnancy, 960–961
 after diagnosing, 960–961
 diagnosis of, 954f, 960
 preconception counseling, 961, 961b
- Teeth
 avulsion, 295
 examination of, 285–286
- Teething, 284–285
 at 6 to 8 months, 105
- Telangiectasia, 712b
- Telehealth, for ear disorders, 502
- Telogen effluvium, 762, 762t, 763f
- Temper tantrums, in early childhood, 128
- Temperament, 43, 44b
 managing, 52–53, 53t
- Temperament and Atypical Behavior Scale
 (TABS), for infants, 113t
- Temperature regulation, in newborn
 assessment, 93
- Temporal lobe, 875t
- Temporomandibular joint (TMJ) disorder,
 293–294
- TEN. *See* Toxic epidermal necrolysis
- Tendinitis, 843
- Tension headache, 882b
- Tension lacerations, 347
- Teratogen, 379
- Teratogenic disorders, 379
- Terbutaline, intravenous, for acute asthma
 exacerbations, 675
- Terminal hair, 709
- Terra firma-forme dermatosis, 760
- Tertiary prevention, 2
- Testes, 800t
 masses located on, 929–930
 torsion of, 930–931, 932t
 undescended, 926–927
- Testicle, undescended or absent, sports and,
 247t–250t
- Testicular masses, 929–930
- Testicular torsion, 930–931, 932t
- Tetanus immune globulin, 619t–621t
- Tethered cord, 899–900, 900f
- Tetracycline, for acne, 741
- Tetralogy of Fallot (TOF), 551–552, 551f
- TFA. *See* Thigh-foot angle
- Thalamus, 875t
- Thalassemias, 769, 782–784
 α -thalassemias, 782
 β -thalassemia trait/minor, 782–784
- Theophylline, for acute asthma exacerbations,
 675
- Theory of Mind (ToM), 87, 87b
- Thermal burns, 349
- Thermometers, types of, and measurement
 sites, 338
- Thigh-foot angle (TFA), 862, 862f
- Thin-basement-membrane disease, 921
- Thiopurines, for ulcerative colitis, 594
- Three-talk model, of shared decision making,
 35–36, 36f

- Thrombocytes, 767, 770
 Thrombosis, renal artery or vein, 404
 Thrush, 721–722, 722t
 Thymus, 800t
 Thyroglossal cysts, 396
 Thyroid-binding globulin (TBG), 814
 Thyroid disorders, 814–817
 anatomy and physiology of, 814, 814b
 hyperthyroidism, 816–817
 hypothyroidism, 814–816, 815b
 Thyroid gland, 800t
 Thyroid hormone, dosing of, 816t
 Tibial torsion, 862
 Tic disorders, 425–426
 Tick-borne diseases, 641–645
 anaplasmosis, 644
 ehrlichiosis, 644
 Lyme disease, 641–644, 642f
 Rocky Mountain spotted fever, 644–645
 Tietze syndrome, 852
 Tinea capitis, 722t, 723–725, 724f, 762t
 Tinea corporis, 722t, 723, 725f
 Tinea cruris, 722t, 726
 Tinea pedis, 722t, 723f, 726–728, 727f
 Tinea versicolor, 722t, 728–729, 729f
 Tissue sensitivity, to toxic agents, 15
 Title V Maternal and Child Health Services
 Block Grant program, 4
 Tobacco smoke, in air pollution, 21, 22t
 Tobacco use, in adolescents, 161–162, 162t
 Toddlers
 breastfeeding, 198, 198f
 elimination pattern in, 217t
 fracture, limping and, 869t–870t
 patterns of sexuality, 72
 urinary tract infections in, 911t
 Toe walking, 867
 Toes, overriding, 866
 TOF. *See* Tetralogy of Fallot
 Toilet refusal syndrome (TRS), 223–226
 clinical findings of, 223
 complications of, 224
 differential diagnosis of, 224
 management of, 224
 patient and family education of, 224–226
 Toilet training, in early childhood, 128–129,
 128t, 129b
 Toileting skills, normal patterns of, 218–219,
 218t, 219b
 Tolerable stress, 41t
 Tongue-tie. *See* Ankyloglossia
 Tonsillectomy, 515
 Tonsillitis, 513–515
 clinical findings of, 513
 complications of, 514–515
 diagnostic studies of, 513–514
 history of, 513
 management of, 514
 physical examination of, 513
 Tonsillopharyngitis, 513–515
 clinical findings of, 513
 complications of, 514–515
 Tonsillopharyngitis (*Continued*)
 diagnostic studies of, 513–514
 history of, 513
 management of, 514
 physical examination of, 513
 Tooth decay, 287–289
 advanced, 287
 clinical findings of, 287, 287f
 early, 287
 prevention strategies for, 287–289
 Tooth eruption
 atypical, 286
 patterns of, 283–284, 284f–285f
 Tooth whitening (bleaching), 296
 Toothbrushing, 288
 Toothpaste, 288
 Topical antibiotics
 for acne, 741
 for eyes, 462–463
 Topical calcineurin inhibitors (TCIs), for
 atopic dermatitis, 688
 Topical corticosteroid preparations, for atopic
 dermatitis, 687–688
 Topical iodine, 289, 296–297
 Topical nasal antihistamines, for allergic
 rhinitis, 683
 Topical skin adhesive, 348
 Topiramate
 for migraine, 886t
 ocular side effects of, 464t
 Torsion
 of appendix testis, 931, 932t
 penis, 926
 testicular, 930–931, 932t
 Tourette syndrome, 425
 Toxic effects, in toxicology, 15
 Toxic epidermal necrolysis (TEN), 751–752
 Toxic exposure, in foods, 184–185
 Toxic shock syndrome (TSS), 719, 720f
 Toxic stress, 41t
 Toxic substances, in toxicology, 12
 Toxic Substances Control Act (TSCA), 20
 Toxicants, in toxicology, 12
 Toxicology, principles of, 12–15
 absorption, 12–14
 distribution, 14
 exposure, 12
 metabolism, 14
 tissue sensitivity, 15
 toxic effects, 15
 Toxins
 in epidemiologic model, 15
 in toxicology, 12
 Toxocara canis, 655
 Toxocarasis, 655–656
 Toxoid vaccines, 266
 Toxoplasmosis, 410–411
 Trace elements, 177t
 Trachea, anatomy and physiology of, 503
 Tracheoesophageal fistula, 400, 401f
 Trachoma, 474
 Traction alopecia, 762, 763f
 Traditional stitches, 348
 Trampoline, safety measures of, 240t–241t
 Transduction, of pain, 329
 Transfusion dependent β -thalassemia,
 783–784
 Transgender
 gender-affirming hormonal transition in,
 809–810
 in LGBTQ, 80–81
 Transient erythroblastopenia of childhood,
 784–785
 Transient hypoparathyroidism, 817–818
 Transient neonatal pustular melanosis, 99t
 Transient synovitis, limping
 and, 869t–870t
 Transient tachypnea of the newborn (TTN),
 398–399, 399t
 Transitional milk, 192
 Transmission, of pain, 329
 Transposition of great arteries, 552, 552f
 clinical findings of, 552
 diagnostic studies of, 552
 history of, 552
 management of, 552
 physical examination of, 552
 Trauma
 dental injuries from, 294–295
 clinical findings of, 294–295
 complications of, 295
 patient/family education in, 295
 limping and, 869t–870t
 scrotal, 930
 to skin and soft tissue, 345–352
 abrasion, 345
 burns, 349–352, 350t, 351b
 contusion, 352
 hematoma, 352
 lacerations, 347–349
 puncture wounds, 346–347, 347t
 Traumatic alopecia, 762, 762t
 Traumatic brain injury (TBI), 885–889
 complications of, 888
 diagnostic studies of, 887–888
 differential diagnosis of, 888
 history, 886
 management of, 888
 patient and parent education
 in, 888, 889b
 physical examination for, 886–887
 symptoms, 888t
 Traumatic herpetic infection, 623
 Traumatic hyphema, 481–482
 Traumatic injuries, in sports, 258–260
 Trendelenburg sign, 845
 Trevor Project, 809
 Triamcinolone (Nasacort AQ), for allergic
 rhinitis, 684t
 Trichomoniasis, 964t–965t
 causing vaginitis and vulvar complaints,
 944t
 Trichotillomania, 762
Trichuris trichiura (whipworm), 603t–605t

- Tricuspid atresia, 552–553, 553f
 clinical findings of, 552–553
 complications of, 553
 diagnostic studies of, 553
 history of, 552
 management of, 553
 physical examination of, 553
- Trisomy 21. *See* Down syndrome
- TRS. *See* Toilet refusal syndrome
- TSCA. *See* Toxic Substances Control Act
- TTN. *See* Transient tachypnea of the newborn
- Tuberculin skin testing, 271, 651
- Tuberculosis, 651–655
 characteristics of, in children, 652t
 complications of, 654–655
 cutaneous, 655
 diagnostic studies for, 653
 differential diagnosis for, 653
 interferon γ release assays for, 652
 management of, 653–654
 Mantoux tuberculin skin test in, 652
 monitoring response to treatment of, 654
 screening tests for, 651–652
- Tuberculous meningitis, 654–655
- Tubulointerstitial proteinuria, 918
- Tummy time, 113
- Tumor, 712b
- Turner syndrome, clinical findings and
 primary care issues of, 386t–390t, 391f
- Tuskegee syphilis study, 28
- 22q11.2 deletion syndrome, clinical findings and
 primary care issues of, 386t–390t, 391f
- Two-generation (or dual) patient, 3
- Tympanic membrane, normal, 487f
- Tympanocentesis, 496
- Tympanogram, 487, 489f
- Tympanometry, 487, 489f
- Tympanosclerosis, 498f
- Tympanostomy, 499–500
- Type 1 diabetes, 818–823, 821t
 clinical findings in, 819
 complications of, 823
 diagnostic studies in, 819
 history in, 819
 management of, 819–823
 medical nutrition therapy in, 822
 ongoing management of, 822–823
 patient and family education in, 823
 physical examination of, 819
 screening for, in family members, 819
- Type 2 diabetes, 821t, 823–827
 clinical findings in, 825
 complications of, 827
 diagnostic studies in, 825
 differential diagnosis of, 825
 history in, 825
 lifestyle changes in, 826
 management of, 825–827
 patient and family education in, 827
 pharmacotherapy for, 826–827
 physical activity and, 232
 physical examination in, 825
 screening guidelines in, 824t, 825
- U**
- UGI series, for gastroesophageal reflux disease,
 576
- Ulcer, 712b
- Ulcerative colitis (UC), 593–594
 clinical findings of, 593
 complications of, 594
 diagnostic studies of, 593
 differential diagnosis of, 593
 features of, 591t
 history of, 593
 management of, 593–594
 physical examination of, 593
 prevention and prognosis of, 594
- Ultrasonography, of renal system, 909
- Ultraviolet (UV) radiation, 463–465
- Umbilical cord
 in newborn assessment, 93
 physical care of, 100
- Umbilical hernia, 403
- Undernutrition, in food insecurity, 7
- Undescended testes, 926–927
- Unilambdoid synostosis, positional molding
 and, 902f
- Unintentional injuries, 299–304
- Uniparental disomy (UPD), 379
- Universal screening, 32
- UPD. *See* Uniparental disomy
- Upper airway obstruction, 505
- Upper arm length, BM–APP, BM–APP
- Upper esophageal sphincter, 566
- Upper gastrointestinal tract disorders,
 569–581
 abdominal migraine, 574
 cyclic vomiting syndrome, 572–574
 dehydration, 569–571
 dysphagia, 569
 eosinophilic esophagitis, 577–579
 gastroesophageal reflux disease, 574–577
 infantile hypertrophic pyloric stenosis, 577
 peptic ulcer disease, 579–581
 vomiting, 569–571
- Upper respiratory tract, 503
 common cold, 510, 511t
 diphtheria, 518–519
 infection, 510, 511t
 nasal foreign body, 520–521
 nasopharyngitis, 513
 pertussis, 519–520, 519t
 pharyngitis, 513–515
 recurrent epistaxis, 522–523
 rhinosinusitis, 510–513
 tonsillitis, 513–515
 tonsillopharyngitis, 513–515
- Urea cycle disorders, 835t, 836
- Ureters, 908
- Urethra, anatomy and physiology of, 908
- Urinalysis, composition of, 909
- Urinary tract infection (UTI), 910–913
 clinical findings on, 911
 diagnostic studies for, 912
 differential diagnosis of, 912
 history of, 911
- Urinary tract infection (UTI) (*Continued*)
 management of, 912–913, 913f, 914b
 patient and family education for, 913
 physical examination for, 911–912
 prevention of, 913
 prognosis of, 913
 prophylaxis for, 914b
 radiologic workup for, 914t, 914b
- Urine
 chemical characteristics of, 909, 910t
 collection of, 909
 diagnostic studies on, 909–910
 microscopic examination of, 909
- Urine dipsticks, 909
- Urolithiasis, 924–925
- Urticaria, 748t
- U.S. Preventive Services Task Force
 (USPSTF), in oral health care, 283
- Uveitis, 479, 479f
- V**
- Vaccination
 acute reactions after, management of, 277
 adverse reactions to, 268
 benefit and risk communication in, 274
 contraindications and precautions to,
 268–272
 invalid, 270–271
 screening for, 271–272, 275
 principles of, 265–266
- Vaccine Adverse Event Reporting System
 (VAERS), 273
- Vaccine Injury Compensation Program
 (VICP), 273–274
- Vaccine Safety Datalink (VSD), 273
- Vaccines. *See also* Immunization.
 active immunity, 265–266
 administration of, 274–277
 safety for, 276
 simultaneous and nonsimultaneous, 267
 allergy to products not present in, 270
 antibody-containing products and, 267–268
 assessment of, 275
 causality in, assessment of, 272
 classification of, 266
 cold chain of, 274
 doses of, 268
 educate patients and/or parents about, 275,
 275f
 inactivated, 266, 277–280
 dengue, 279
 diphtheria-tetanus-acellular pertussis, 271
Haemophilus influenzae, 278
 hepatitis A, 278
 hepatitis B, 278
 human papillomavirus, 279
 influenza, 280
 meningococcal, 279
 pneumococcal, 278, 279b
 polio, 278
 for infectious disease prevention, 615–656
 interval between doses of, 267
 live attenuated, 266, 280–281

- Vaccines. *See also* Immunization (*Continued*)
 injectable, antibody-containing products and, 267–268
 measles, mumps and rubella, 280
 nonsimultaneous administration of, 267
 oral and intranasal, antibody-containing products and, 268
 rotavirus, 280
 pain relief for, 277
 passive immunity, 265
 safety programs for, importance of, 272–274
 storage and handling of, 274
 timing and spacing of, 266–267
- Vaccinia immune globulin intravenous, 619t–621t
- VACTERL association, clinical findings and primary care issues of, 386t–390t
- VAERS. *See* Vaccine Adverse Event Reporting System
- Vagina
 after onset of puberty, 935–938, 937f, 937t, 937b
 before puberty, 934–935, 935f–936f, 935t
- Vaginal bleeding, prepubertal, 943
- Variable age of onset, definition of, 378t
- Variable expressivity, definition of, 378t
- Varicella immune globulin, 619t–621t
- Varicella zoster virus, 625–626
 clinical findings in, 625–626
 complications of, 626
 congenital, 412–413
 diagnostic studies for, 626
 differential diagnosis and management of, 626
 patient and family education in, 626
 vaccine for, 281
- Varicocele, 928–929
- Varus overload, of elbow, 871t
- Vascular hemophilia, 789
- Vascular malformations, 757b
- Vasculitis/vascular disease, sports and, 247t–250t
- Vasoactive intestinal peptide (VIP), 878t
- VCUG. *See* Voiding cystourethrogram
- Vegetarian diets, 183–184, 184t
- Vellus hair, 709
- Velocardiofacial syndrome, 379. *See also* 22q11.2 deletion syndrome.
- Ventral roots, 875t
- Ventricular failure, 553
- Ventricular septal defect (VSD), 549, 549f
 clinical findings of, 549
 diagnostic studies of, 549
 history of, 549
 management of, 549
 physical examination of, 549
- Veramyst. *See* Fluticasone furoate
- Vesicle, 712b
- Vesicoureteral reflux, 914–916
 clinical findings on, 914
 diagnostic studies of, 914–915
 grading of, 915f
 management of, 915, 915t
 patient and family education for, 915–916
 prevention of, 915–916
 prognosis of, 915–916
- VICP. *See* Vaccine Injury Compensation Program
- Video swallow study, for gastroesophageal reflux disease, 576
- Violence, 303–304, 303b
 intimate partner, 304
 prevention of, 55, 55b–56b
- Viral conjunctivitis, 474–475
- Viral diseases, 615–617
 avian influenza, 628
 coronaviruses, 639–640
 enteroviruses, 615–617
 nonpolio, 615–617
 poliovirus, 617
 erythema infectiosum, 634–635, 634f
 Hantavirus pulmonary syndrome, 638–639
 hepatoviruses, 617–622
 herpes family, 622–626
 herpes simplex virus, 623
 infectious mononucleosis syndrome, 624–625
 roseola infantum (exanthem subitum), 625, 625f
 varicella zoster virus, 625–626, 627f
 human calicivirus infections (Norovirus and Sapovirus), 639
 human immunodeficiency virus, 628–632
 human pneumovirus (metapneumovirus), 639
 influenza, 626–628
 measles (Rubeola), 632–633
 Middle-Eastern respiratory syndrome, 640
 mosquito-borne, 636–638
 dengue virus, 637–638
 West Nile virus, 637
 Zika virus, 636–637
 mumps, 633–634
 parainfluenza, 635
 potential emerging and reemerging, 640–641
 rubella (German or 3-day measles), 635–636
 tick-borne, 641–645
- Viral infections, of skin, 729–734
 herpes simplex, 729–731, 730f, 731t
 herpes zoster, 731–732, 731f, 731t
 molluscum contagiosum, 732–733, 733f
 warts, 733–734, 734f, 735b
- Viral pneumonia, 524, 525t
- Viruses, 610
 modes of transmission in childcare settings, 615t
- Visceral larva migrans (VLM), 655
- Visceral pain, 330b
- Visual disorders, 466–471
 amblyopia, 466, 466b
 blepharoptosis, 467
 cataracts, 468–469, 468f
 with cerebral palsy, 897
 glaucoma, 469
 nystagmus, 467–468
 refractive errors, 466, 466b
 retinoblastoma, 470–471
 retinopathy of prematurity, 469–470
 strabismus, 466–467, 467b
- Visual reinforced audiometry (VRA), 488t
- Vital signs
 in cardiovascular system assessment, 538–539, 538t
 of infants, 103
- Vitamin supplement, use of, 173
- Vitamins, 173, 174t–175t
 in adolescent, 183
 for athletes, 243t
 in early childhood, 181
 in human milk, 193
 in infants, 181
 in middle childhood, 181–183
- Vitiligo, 761
- Vocalizations, at 6 to 8 months, 110
- Voiding cystourethrogram (VCUG), 910
- Volvulus, malrotation with, 400–401
- Vomiting, 569–571
 clinical findings of, 570–571
 complications of, 571
 diagnostic studies for, 571
 differential diagnosis of, 571, 571t
 history of, 570
 management of, 571
 patient and family education in, 571
 physical examination of, 570
- Vomitus, blood in, 407
- von Recklinghausen disease. *See* Neurofibromatosis type 1
- von Willebrand disease, 789–791, 790t
- VRA. *See* Visual reinforced audiometry
- VSD. *See* Vaccine Safety Datalink; Ventricular septal defect
- Vulvar ulcers, 945, 945f
- Vulvovaginal infections, 941
- Vulvovaginitis
 in adolescents, 943, 944t
 prepubertal, 941–942, 942t
- Vygotsky's theory, of child learning, 86–87
- W**
- Warts, 733–734, 734f, 735b
- Waste products, regulation by genitourinary system, 908
- Water, in human milk, 192
- Water-soluble vitamins, 173
- WBCs. *See* White blood cells
- Weaning, from breastfeeding, 199
- Weight, of infants, 103

- Well-being, 38–39
 elements of, 39t
 theories of, 38–39
- West Nile virus, 637
- Wet dressings, 713
- Wet wrap therapy (WWT), for atopic dermatitis, 689
- Wheal, 712b
- Whipworm. *See* *Trichuris trichiura*
- White blood cell count, 791–792
- White blood cells (WBCs)
 disorders of, 791–792
 alterations of granulocytes, 792
 dysfunction of, 792
 lymphocytosis, 792
 in infectious disease, 613
 in urine, 909
- White dermatographism, atopic dermatitis and, 687
- Whooping cough, 519
- Williams syndrome, clinical findings and primary care issues of, 386t–390t, 391f
- Wilms tumor, 925–926
- Windows of vulnerability, 12
- Winnicott, Donald, 85–86
- Winter sports
 helmets for, 241, 242b
 safety measures of, 240t–241t
- Wireless pH monitoring, for gastroesophageal reflux disease, 575
- Wisdom teeth, 284
- Wiskott Aldrich syndrome, clinical presentation of, 703t
- Wounds
 cleansing of, for lacerations, 348
 closure of, 348
 debridement of, 348
 exploration of, 348
 puncture, 346–347, 347t
- WWT. *See* Wet wrap therapy
- X**
 X-linked dominant inheritance, 378
 X-linked inheritance, 377–378
 X-linked recessive inheritance, 377, 377f
- Y**
Yersinia enterocolitica, 598t–600t
Yersinia pseudotuberculosis, 598t–600t
- Z**
 ZES. *See* Zollinger-Ellison syndrome
 Zika virus, 636–637
 Zollinger-Ellison syndrome (ZES), 579